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ABSTRACT
The role and mechanism of action of 0l·adrenoceptors in adrenergic spinal
antinociceplion is uncertain. ol-Adrenoceplors are normally excitatory in the eNS,
suggesting thai any intlibitory effect on nociception must be indirect. Recently, we
shovled that intrathecal (I. t.) 0l-agonists potentiale 02-induced spinal antinociception
in the rat by a 6-receptor mediated, enkephalin-dependent process. If enkephalins,
released from spinal ir:ternl'uronr., mediate the antinociceptive effect of OJ-
adrenoceptors, then non-seler;live o-agonists (i.e. norepinephrinf.l; NE) should
exhibit cross-tolerance to 6-agonists (I.e. DAOLE), but not 10 lJ·agonists (i.e.
morphine), in the spinal cord. Conversely, the anlinociceptive effect of o.-selective
agonisls (i.E'. dexmedetomidine; OX) should be unaffected by spinal opioid
tolerance. To test iilese hypotheses, male, Sprague-Dawley rats (3oo-400g) were
continuously infused with i.t. saline (1 1J11h), morphine (MOR; 5, 10, or 20 IJgIh) or
DADlE (10 IJgJh) for 6 days using ALZET osmotic minHxJmps. Antinociception was
assessed using the tail flick (TF) test. In an inilial time course study, significant
recovery from DADlE and MOR tolerance did nol occur until day 3 and 4 post-
infusion (PI), respectively. In subsequent cross-tolerance experiments, NE and OX
dose-response curves were determined on days 1 and 2 PI for DADLE-pretreated
rats, and on days 1-3 PI in MOR-pretreated rats. The table of EDso ratios for 1.1. NE
and OX in opioid- and saline-infused animals demonstrates that NE exhibits
significant (t-) cross-tolerance to OADlE, but not morphine. No cross-tolerance was
observed between OX and DAOlE.
INFUSION TEST DRUG EOsoCopioid)IED~saline)
MOR5 NE 1.12
MOR 10 NE 1.51
MOR20 NE 1.35
DADLE 10 NE 2.504*,
DADLE 10 DX 0.66
In separate groups of rats, i.p. naloxone significantly attenuated the antinociceptivll
effect of MOR, but not DADLE, on day 1 of infusion (tima of peak antinocicep!ion);
i.p. naltrindole significantly antagonized DAOlE, but not MOR. These data indicate
that~· and 6-receptor selectivity was retained during infusion, consistent with the
different cross-tolerance results to NE. The marked antagonism of Lt. OX by Wyelh
27127, but nol by prazosin, confirmed the 02-selectivity of DX at the doses used.
The results of this study are consistent with the hypothesis that 0l-adrenoceptors
facilitate the release of enkephalins in the spinal cord which, in turn, effect
antinociception by a 6-receptor mechanism.
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1.0 INTRODUCTION
1.1 Statement of tho Research Problem
The perispinal administration of a~adrenoceptor agonists produces robust
antinociceplion in a variety of Etxperimenlal animals, without affecting muscle
strength, motor reflexes and locomotor activity (see review by Yaksh, 1985).
Extensive pharmacological studies using receptor-selective agonists and
antagonists have yielded structure aCtlvity profiles Indicallve of an anlinocicepllve
affect mediated by spinal 02-adrenoceptors. These rasults are consistent with
receptor binding and autoradiographic dala demonstrating the dense localization of
o2-binding sites in the substantia gelatinosa (UnnerstaJI et al., 1984; Sullivan et al.,
1987; Simmons (;I1d Jones, 1988), and the inhibitory role played by °2-
adrenoceptors in the eNS. Thus, the activation of spinal 02-adrenoceptors has
been shown to inhibit neurotransmitter release from the central terminals of primary
afferent pain fibers (Howe and Zieglgansberger, 1987; Ueda et af., 1995); and to
depress high threshold stimulus-evoked activity in wide dynamic range neurons
(Fleetwood-Walker et af., 1985; Omote et al., 1991). Importantly, the functional and
behavioral inhibition mediated by spinal 02-adrenoceptors appears to be
independent of endogenous opio!d systems (Figure 1).
The contribution of 0l-adrenoceplors in spinal adrenergic anlinociceplion is
less clear. Radioligand binding studies and quantitative autoradiography indicate
a homogeneous distribution of 0l-.adrenoceptors throughout the grey matter of the
DX
~ (1)
/02_ANTINOCICEPTION t
NE POTENTIATION
~ (2) 6 t
/01-ENK- J1_ANTINOCICEPTION
MX
Figure 1. Proposed mechanisms underlying spinal adrenergic
antlnociceptlon, and the hypothesized oplold link to Ql·adrenoceptors.
Activation of the o\-receptor by drugs such as methoxamine (MX) or norepinephrine
(NEl may facilitate the release of enkephalins which act preferentially on 6-opioid
receptors 10 effect anlinociception. Co-activalion of 0 1" and 02-receptors could lead
to the potentiation of spinal adrenergic analgesia via an opioid-a2 interaction.
rat spinal cord (Giron etal., 1985; Sirrvnons and Jones, 1988; Roudet etal., 1993).
That these binding sites are functionally coupled is demo:1straled by the
pharmacological effects of aI-selective agonists and antagonists on motor,
aulooomic and sensory function in the spinal cord of experimental animals (Davis
and Astrachan, 1981; Astrachan et al., 1983; Howe et al., 1983; Yaksh, 1985;
Loomis and AnJnachalam, 1992). In the [alter case, intrathecal (i.t.) a,-agonists like
methoxamine and phenylephrine significantly increased the thermal nociceptive
threshold of conscious rats (tail-flick and hot-plate tests) (Howe at al., 1983; Yaksh,
1985). Unlike 02-agonists however, antinociceptive doses of methoxamine and
phenylephrine facilitated motor reflexes, raising questions about the selectivity of
acllon and thus the potential of at-agonists as spinal analgesic drugs.
Nevertheless, the contribution of ot-adreno~eptors in sp,nel adrenergic
antinociceplionlanalgesia has never been disproved by experimental data.
0t·Adrenoceptors aro excitatory in the eNS (Aghajanlen and Rogawski,
1983), enhancing neuronal depolarization and Ca.... influx. Consequently, the ability
of a,-agonists 10 effect spinal anlinociception suggests that they activate, or at loast
facilitate, an inhibitOfY neural Input on primary afferent and/or projection neurons in
nociceptive pathways. Enkephalin, one of three major endogenous opioid peptides,
is known to selectively modulate nociceptive transmission in the spinal cord (see
review by Yaksh, 1993). Enkephali~tajning neurons, and the i5-opioid receptors
that are believed to mediate the biological activity of enkephalin, are densely
kx:alizedin the dorsal hom (Dado et al., 1993; Todd and Spike, 1992; Ruda et aI.,
1986). There is an extensive literature documenting the antinociceptiv8 synergy
between opioids, including enkephalin analogues, and o-agonisls, following co-
ir1edion into laboratory animals (Ossipovet al., 1990; Omole et aI., 1991; Roerig
et al., 1992). A similar interaction has also been reported in tlunans (Molsch et al.,
1990; Gordon et 81., 1992; Siddall et aI., 1994). Recent studies in our laboratory
have shown that, in the rat, a threshold dose of Lt. methoxamine significantly
potentiates the antinociceptilJe effect of the highly selective 02-agonisl.
dexmedetomidine, via a O~receptor-mediated, enkephalin-dependent process
(loomis et al., 1992a, 1992b, 1993). Although a pharmacokinetic interaction
between the lYiO drugs could not be totally excluded, the data suggest that
methoxamine, and presLITlably other a,-agonists, augment the antinociceptive
activity of a 2-agonists in the rat spinal cord by facilitating the local release of
enkephalin (see Figure 1). Extracellular enkephaJin woutd then be free 10 inhibit
nociceptive transmission ltV"ough its normal opioid receptor-coupled mechanisms
in the spinal dorsal hom. In this manner, the co-adivation of al~ and °2-
adrenoceptors with appropriate receptor agonists could induce, albeit indirectly, an
02-opioid interaction that is known to be both supra-additive and antinociceptive.
Considering thefacl that norepinephrine (NE), the neurotransmitter released from
bulbospinal neurons of the endogenous pain control system, is a non-selective a·
agonis~and the proximity of enkeptlalin-containirltl neurons 10 the terminals of these
noradrenergic fibers. ~ is possible that such an interaction also underlies the
modulatory effect of NE. at least in the rat.
If the hypothesis illustrated in Figure 1 is correct, then non-selective a-
agonists like NE, and al"selective agonists like methoxamine, should exhibit cross-
tolerance to O-agonists in the rat spinal cord. Conversely. highly selective °2-
agonisls such as dexmedetornidine (DX) should be unaffected by tolerance to Lt.
6-agonists. Using dose-response analysis, we determined the degree of cross-
tolerance between opioid- and oieceptor subtype selective agonists in the rat tail-
flick test. Opioids were delivered by continuous i.1. infusion using ALZET osmotic
mini-pumps. The antinociceptive effect of the LI. a-agonist was determined in
tolerant and non-tolerant animals by means of dose response analysis. Agonist
selectivity was verified using receptor subtype-selective antagonists.
1.2 Spinal Op{old Analgesia
Although opioids unquestionably produce analgesia by a supraspinal action,
basic and clinical studies have shown lhatlhey also act directly in the spinal cord
to inhibit Ihe transmission of pain (see reviews by Yaksh and Noueihed, 1985;
Yaksh,1993). Electrophysiological studies in animals first demonstrated the potent
depressant actions of morphine on the electrical responses of spinal neurons
evoked by noxious stimuli; an effect antagonized by specific opioid antagonists
(Belcher and Ryall, 1978; Duggan et al., 1977; Sastry, 1978). The conclusion from
6these studies was that, at appropriate doses, opioids could selectively depress the
activity of small afferert fibres Involved in pain transmission without affecting large
diameter fibers.
The development 0( the technique of chronic catheterization of the
subarachnoid space in several animal species (Yaksh and Rudy. 1976a) made it
feasible to apply oploids to the spinal COfd of conscious animals. Using this
procedure, spine:11 opioids were shown to produce segmental analgesia thai was
dose-dependent, stereospecific and antagonized by naloxone (Yaksh and Rudy,
1976b). AI analgesic doses, the acule i.t. injection of opioids in animals has no
major effed.00 respiration, mJSCIe activity Of autonomic funct!o.l (Yaksh and Rudy,
1976b), although large dose can produce hind limb weakness and convulsions
(Frenk. et af., 1984; Watkins etal., 1984).
Withrl three years of the first report of spinal opioid analgesia in rats. spinal
Ill(WJlhine was lested il humans (Wang et aI., 1979). Wang and cowor1ters reported
thatlhe i.t ~dO.5-1.0mg of morphinerelie....ed se....ere back and leg pain in
patients with iloperable maliglatlcies of lhe genilOllfin<ry trad fa up to 24 h. Since
that fitst dinjcal report, spinal opioids have been used successfully in the treatment
of postoperative pain, obstetric pain, pain associated with trauma, deafferentation
pain and pain arising from chronic illness, including cancer. In the clinical
management of pain, both i.t. and epidural routes of adminislration are used.
The selective and localized effect of spinal opioids offers a number of
advantages over other forms of pain control. First, the duration of analgesia is
longer with spinal iieCtiOn Ihan with systemc administration d the same agent. In
humans, systemically administered morphi'le (10 mg, s.c.) produces analgesia
lasting for 4-5 h (Jaffe and Martin, 1990), while the equivalent dose administered
epldurally is effeclive for 4310 18 h (Cousins and Mather, 1984). The duration of
spinal analgesia permits n longer dosing intorval dUfing repeated administration,
thereby providing more freedom to !he patient and the allendanlmedical personnel.
A second advantage Is thai the I. t. 1)1" epidural injection of oplolds concentrates the
drug near Its site otaction in the dorsal hom Consequenlly, effective analgesia can
be produced with lower doses of oplolds than those required for systemic
actninistration. For example, in the treatment 0( cancer pain, doses of I.t. morphine
ranging from 0.5-16 mg, iJl'ld doses ofepidlsalmorphrle ranging from 2-30 mg have
been reconvnended (Payne, 1987). This is il contrast to oral doses of 30.00 1'119
(Foley and Inturrisi, 1987) Vrtlich must also be given more frequently than Lt.
mcrphine. As a result, the concentration of aug eventually reaching the systemic
cil'QJlation after spinal injection is low and the incidence of adverse effects mediated
at supraspilal sites, such as mental douding and drowsiness, is reduced (Payne,
1987). A third advantage is that the selective action of spinat opiolds avoids the
complication of sympathelic blockade associated with spinal anesthesia. Overall,
the absence of autonomic and .motor effects with spinal oplolds provides patients
with adequate pain control over long periods of time, while remaining ambulatory
and having an otherwise functional sensorium
The advantages afforded by spinal opioids have been tempered however by
the development of adverse effects, including delayed respiralory depression,
pruritus, urinary retention, tolerance and withdrawal. Respiratory depression is a
life-threatening consequence of spinal opioid use that generally occurs 6·12 h after
injection. The use of more lipid soluble opioids such as fentanyl has partially
overcome this problem but patients do require continuous and intensive monitoring,
In the management of chronic pain, tolerance is a factor limiting the use of spinel
opioids. For example, of 62 palients receiving U. morphine for cancer pain, 74% of
the palients experienced effective analgesia without severe respiratory depression
or los5 of motor or sensory functions (Wang, 1985). Many of the patients were
effectively managed as outpatients. However, 43% of patients given repeated i.l.
morphine injections, and 50% of patients receiving continuous i.1. infusion via drug
pumps developed tolerance and severe complications (pruritus, sphincter disorder,
and somnolence). In addition, withdrawal in patients receiving epidural opiates has
been reported following discontinuation of treatment or when treatment is
antagonized by substitution of a pure agonist with a partial agonist or agonist·
antagonist (Cousins and Mather, 1984). While i... oploids are useful in the
management of chronic pain, it is clear that more effeclive drugs or combinations
of drugs are needed 10 reduce the problems of tolerance and the incidence of
adverse effects. Moreover, some types of pain, partiCUlarly those of a non·
malignant nature, do not respond to opioids administered either spinally or
systemically (I.e. neural injury pain) (~r and Meyerson, 1988; Siddal at al., 1994).
Synaptic transmission between primary afferent fibres and second order
neurons thai comprise the spinothalamic trad is SUbject to modulation by a I~; Je
number of neurotransmilterslneuromodulators within the spinal cord (subslant;.a P,
VIP, CCK, somatostatin, neUTotensin, angiotensin, mel-enkephalin, bombesin,
excitatory amino acids, GABA, norepinephrine, and serolonin)(HOkfelt et a/., 1977;
Barber at aI., 1978; Salt and Hill, 1983; Basbaum and Fields, 1984; Besson and
Chaouct1, 1987; Yaksh, 1993). Drugs that mimic the actions of spinal
neurotransmitters or neuromoduJalors that inhibit pain transmission could be useful
as spinal analgesics. To the eldent that these drugs exert their effect through a
receptOf subtype and an intracellular mechanism that is distinct from those of the
opioid peptides, they could be used as adjuncts with spinal opioids ()( as an
alternative therapy to optimize analgesia.
1.3 Endogenous Pain Control System ~ Descending Inhibitory Palhways
Anatomical and pharmacological studies have identified descending and
Intrinsic neuronal systems in the spinal cord that modulate nociceplive transmission
in the dorsal hom (Dahlstrom and Fuxe, 1965; Basbaumand Fields, 1984; Fields
and Basbaum, 1989). Neurons utilizing serotonin (S-HT) as a neurotransmitter
descend from the nucleus raphe magnus in the medulla through the dorsolateral
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funiculus of the spinal COfd to terminate in the outer laminae of the dorsal horn.
Similarly, noradrenergic neurons descend from nuclei in the pons, including the
locus coeruleus (LC), the medial and lateral parabrachial nuclei, nucleus
subcoeruleus, the AS nucleus, and the A7 nucleus (see reviews by Proudfit, 1988;
Jones, 1991) tolarminata in theouler dorsal horn. Following their release in the
spinal cord, NE and 5-HT inhibillhe evoked discharge of spinothalamic neurons.
These descending (bulbospinal) inhibitory pathways are thought to provide
aregulatory feedback loop, whereby nociceptive transmission through the dorsal
horn is modulated by afferent inputs reaching the thalamus, periaqueduclal grey
(PAG) and brainslem. For example, afferent input In the spinomesencephalic tract
(and probably other tracts ascending through the anterolateral qUadrant of the spinal
cord), as well as Input from the hypothalamus, thalamus and cortex, activate the
PAG. By mechanisms that remain poorly understood, the PAG appears to
coordinate the response of these inhibitory bulbospinal pathways to ooxious
stimulation (Fields and Basbaum, 1969).
The discovery or these monoaminergic (and other) systems, the identification
of the neurotransmitters underlying their modulatory effect, and subsequent studies
of their release and spinal pharmacology, provided important evidence for non·
opioid modulation of noxious sensory processing in the spinal cord of experimental
animals.
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1.4 HE and 5--HT E"ect Spinal Antinoclception
CoosiSIet'ltwith \heir inhibitory role in the spinal cord, and like the opioids, NE
and 5-HT werfo shown 10 depress the discharge of dorsal hom neurons driven by
noxious stimulation (Headley et aI., 1978). In subsequent rodent behavioral studies,
1.1. NE and 5-HT significantly inhibited the escape responses evoked by noxious
thermal stimuli, at doses that did not affect muscle strength. normal reflexes or
locomotor activity (Yaksh and Wilson. 1979; Yaksh and Reddy, 1981; Milne at 8/.,
1985). However, NE was approximately 30 limes more potent than 5·tH. The spinal
entinociceptive effect of NE could be blocked by a·, but not j3-adrenoceptor
antagonists, suggesting the former to be the relavant receptor subtype.
Antinociception was also potentiated by monoamine oxidase inhibitors and
monoamine reuptake blockers (Kuraishi et 81., 1979; Reddy et al., 1980; Reddy and
Yaksh, 1960; Yaksh and Wilson, 1979). In view of the fact that vasoconstrictors,
such as angiotensin II, and vasodilators. such as bradykinin, given i.l., were without
effect in these behavioral tests, it was concluded that Lt. monoamine-induced
en!inociception is not secondary to changes in spinal cord blood now. Rather, it is
adirect effect on sensory neurons In the spinal cord, consistent with the results of
electrophysiological studies described above. While their short time course of action
(<30 min) makes Ll. NE or 5-HT impractical for clinical use, these studies provided
direct eKPBrimenlal evidence thai monoamines could selectively inhibit the
behavioral responses to noxious stimuli in conscious behaving animals.
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1mportartIy, the ninociceptive effect of i.t NE is shared by other a-agonisls.
For example, low dose i.t. clonidine produced significant anlinociception withool
dishxbing motor flnction (Yaksh and Wdson. 1979; Yaksh and Reddy. 1981; Milne
et al., 1985b). '" general, the rank order of potency of a-agonists in behavioral tests
of nociception paclllels that observed in other pharmacological preparations utilizing
a-adrenoceplors. A fundamental question arising from these results, and one
critical for the rational selection of an adrenergic spinal analgesic, is the
a~adrenoceplor sublype(s) mediating anlinociception in the spinal cord.
1.5 Spinal AdrenergIc Receptors and Antinoclceptlon
1.5.1 Binding Studies
Early binding studies with radiolabelled ligands that could disaiminate
between 0,·, Q)" and B-adrenoceptors confirmed the presence of all UYee binding
sites in the spinal cord (Jones etaJ.• 1982). Autaadiograpny with [\-4)WB-4101, an
0l-selective antagonist. indicated a moderate density of a,-binding sites in the
substria gelatinosa and the spinal trigeminal r'll.deusoflhe rat (Young and Kuhar,
1980). Similar studies with I'Hpara-aminoclonidine showed the highest density of
arbinding sites in rat and human spinal cords to be in the substantia gelatinosa and
the intennediolateral cell column (Young and Kuhar, 1980; Unnerslall et al., 1964).
In contrast, 02-binding sites were very low in the ventral hom. Using the fluorescent
probe, 9-amino-acridine propranolol, a high density of lWeceptors was located in the
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region of the ventral hom containing a-motoneurons (Melamed et aI., 1976). e-
Receptor blRing was sparse in the dorSal hom except in the substantia gelatinosa
where moderate B--receptor binding was obS8l'Ved.
In a SlbsequeIt study,lhe lesioning of clescencflllQ adrenergic fibers with 6~
hydroxydopamine was shown to have no delectable effed on the density of a,~
binding sites In the gray mattllf of the cal lumbar spinal cord (Howe et af" 1987a).
These data io:licate that the majority of o,-binding siles are present on cells in the
lumbar spinal gray maller, and oot on Ihe spinal terminals of descending adrenergic
neurons. This is further supported by autoradiographic data indicating thai Qa-
adTenoceplors are located on spinal dorsal hom neurons in the rat (Sullivan et af.,
1987). Howe at al. (1967b) also showed thai a unilaleral ganglioectomy of the
dorsal roots in the cat yieldedonly a 20% reduction in \he total runber a o,·binding
sites in the ipsilateral kmbar usal hom. It was inferred that the remaining 80~" of
02"s1Ies are post-synaptic 10 the primary afferents neurons (Le. 00 projection
neurons andtor intemeurons~
1.6.2 Pharmacologlc.I Studies
The observation of 0,", 02- and B-binding sites In the substantia gelatinosa,
an Bias of the dorsal hom knO'Ml to modulate nociceptive Input, raised the possibility
that all three types of adrenergic sites could be Manalgetically cou~it:Od". However,
the l.llnjection of the lHeceplor agonls~ Isopropylnorepinephrine, had no effecl on
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the behavioral responses of rals 10 thermal nociceptive stimuli, Likewise, U. NE~
induced antinociceplion was not reversed by the B.antagonist, propranolol (Reddy
et a/., 1980). In contrast, a variety of o-8gonisls, with differing selectivities for ex 1~
and a 2-adrenoceptors, produced significant, dose-dependent antinociception
following I.t. administrallon to laboratory animals (Reddy et al., 1980; Yaksh and
Reddy, 1981; Milne etal., 1S8Sb; Loomis et al., 1965; Shermanet 81., 1987); an
effect thai was dose-dependenlly inhibited by phentolamine, but not by propranolol
(Reddy et al., 1980; Yaksh and Reddy, 1981; Milne et al., 1985b). The resulting
rank oo:ler of potency in \he rat tail nick, hoi plate and acetic acid writhing lests was:
ST·91 (az·selective agonist) = NE > methoxamine (at,selective agonist) >:>
isopropylllOrepinephrine = O. Similar results were reported in the primate shock
Illration test (Yaksh and Reddy, 1981). Thus, the ability of i.1. NE and other
adrenergic agonlsts to elevate nociceptive threshold appears to be uniformly
mediated by a-atienoceptors.
To assess the relative role of spinal 0,- and o2-adrenoceptors in
noradrenergic anlinociceplion, dose-response studies using a," end 02"seleetive
antagonists were undertaken. Intrathecal yohimbine significantly inhibited i.t. ST-91
in the tail flick and hot plate tesl. Consistent with its selective blockade of 02·
adrenoceplors in this experiment, the 1050 of yohimbine was 1f1oth that of Lt.
prazosin (Howe etal., 1983). In contrast, i.l. prazosin was approximately 10 times
more potent yohimbine in antagonizing the anlinociceptive effect of i.1. methoxamine
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and NE. The relative OI'der of adivity iii rsvel'Smg thermal anlinociception with i.l
NE was: prazosin. phentolamine, ralJINOIscine, yohimbine. coryanthine, propranolol
(=0) (Yaksh, 1985; unpublished observations). The relative order of activity in
fevefSing ST·91 was: yohimbine, ral.MlOlsdne, prazosin, phentolamine, coryanlhine.
propranolol (=0) (Yaksh, 1985). Thus, the dominant population of adrenergic
receptors mediating spinal anlinociception in the rat exhibit a pharmaoological profile
characteristic of Q 2-adranoceplOfs. Nevertheless, I.t. NE (8 nOIHelective a-agonist)
was more potently antagonized by Lt. prazosin than Lt. yohimbine (Howe et aI"
1983; unpublished observations), suggesting that spinal a,-adrenoceplors may
contribute to the overall inhibitory effect.
Indeed, a,-selective agonists, including methoxamine, cirazoline and
phenylep/Vine, were shown to inhibit the behavioral responses to thermal and
mec:hanical nociceptive stimuli (Reddy et ai., 1980; HCM'8 et al., 1983; Yaksh, 1985;
l.WlpLt>Iished observatials). A noo-seledive effect at 0l...adrenoceptors, particularly
at high doses, could not account for these results as methoxamine was more
potenlly antagonized by prazosin than yohimbine (Howe at al., 1983). The
a,-agonists had a lower maximum antinociceplive effect compared to NE or to the
02-seleclive agenists. In agreement with this observation, phenylephrine and
cirazoline were shown to be less efficacious than NE In stimulating the maximum
accumulation of inositol phosphate (Chiu et al., 1987), the second messenger
coupled to o,-adrenoceptors (Minneman and Johnson, 1984). However,
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antinociceplive doses of i.t. methoxamine and phenylephrine also produced cisar
molor effects. In the primate, these include hind limb tremor and exaggerated reflex
withdrawal responses to non-oociceptlve stimuli. In the rat, dose-dependenl,
cutaneous hyperreflexia, clonic flexion of the hindlimbs, rigidity and serpentine
movements of the tail have been observed (Yaksh, 1985; unpublished
observations). These exaggerated reflexes, consistent with the facilitatOfY role of
spinal Q 1-adrenoceptors on motor neurons (Tanabe et al., 1990), could explain the
apparent lower efficacy of a 1- as compared to Q 2-agonisls given spinally. At the
very least, the measurement of the behavioral responses to nociceptive stimuli
following 1.1. a,-agonists, involving both reflex and supra-spinally co-ordinaled motor
responses, are confounded by such an effect. Thus, the role of spinel
Q,-adrenoceptors In adrenergic antinociception has not been completely or
accurately investigated.
1.6 Cellular Mechanisms Underlying Spinal af~ and a,..Adrenoceptor-
Mediated Anl/noc/ception
The activation of neuronal 02-adrenoceplors results in the opening of
outwardly directed K" channels. This causes a hyperpolarization of the cell, which
results in the suppression of neuronal firing (see figure 3) (Nakamura at al., 1961;
Egan et af., 1983). As well, 02-adrenoceptor activation can inhibit voltage sensitive
calcium channels (Williams and North, 1965), thereby suppressing Cau influx and
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the fusion of neurotransmitter-filled vesicles with the synaptic membrane. These
actions on ion channels are believed to be mediated through a G-protein (Dunlap
at a/., 1987). Consistent with these observations, it has been shown that a·
agonisls, ading primarily through the 02-adrenoceptor (Kuraishi et al., 1985; Go and
Yaksh, 1987) can inhibillhe release of substance P in mammalian spinal cords,
using both in vivo (Kuraishi at a/., 1985; Go and Yaksh, 1987) and in vitro (Pang and
Vasko, 1986) preparations. Similarly, 02.receptor activation has been shown to
inhibit the release of calcitonin gene-relaled peptide (CGRP) (Holz at aI" 1989). 02-
Adrenoceptors also hyperpolarize receiving neurons in the spinal cord and thus
attenuate their response to neurotrCi:1smilters released from adjacent nerve
terminals.
Q 1-Adrenoceptors have been shown to regulate the level of excitability of
cells, rather than participating in the transmission of rapid signals (Aghajanian and
Rogawski, 1963). Using iontophoretic drug delivery and intracellular recording from
motoneurons in the facial nucleus, NE produced a long-lasting depolarization that
was associated with a decrease in the membrane conductance to K·, Thus, NE
brought these cells closer to the threshold for action potential generation, explaining
the ability of aI-receptor activation to facilitate neuronal transmission (Aghajanian
and Rogawski, 1963), Electrophysiological studies using in vitro spinal cord
preparations have also shown that NE can excite unidentified dorsal horn neurons;
an effect mediated by Q 1-feceptors (North and Yoshimura, 1964),
16
Hence, it appears that Q,. and Ql-adrenoceplOl'S affect K" conductance In
opposing ways. Q1-Adrenoceplor activation inaeases K" conductance leading to
cell hyperpolarization arld lhe inhibition of neuronal transmission. In contrast, at·
adrenoceptor activation decreases K" conductance leading to depolarization and an
increase in netXOflal excitability. Unlike the electrophysiological results of the a,·
agonists, these dala appear inconsistent with an anlinocicepljYB sffed. Indeed.
electrophysiological recordings have confirmed the depolarization of many dorsal
horn neurons following the local application of NE or al-agonists (North and
Yoshimura, 1984; Todd and Millar, 1983; Howe and Zieglgansberger, 1987).
1.7 a('Fac/lltation of Enkephafinerg;c Inhibition In 'he Rat Spinal Cord
In view of the depolarizing effect of 0l-adrenoceptors in the eNS (Aghajanian
and RogawslO, 1983), the ability of o,-agonists to effed spinal anlinociceplion
suggests that they activate, Of at least facilitate, an inhibitory f'le\I'al input on primary
afferent and/or projection neurons in nociceptive pathways. Enkephalin, one of
three major endogenous opioid peptides, is known to selectively modulale
nociceptive transmission in the spinal cord (see review by Yaksh, 1993).
Enkephalin..containing neurons, and the 6-opioid receptors that are believed to
mediate the biological activity of enkephalin, are densely localized in the dorsal hom
(Dado etal., 1993; Todd and Spike, 1992; Ruda et 81" 1966). Enkephalin is known
to be released in the spinal cord following a noxious stimulus in a number of
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species. Noxious mechanical stimulation has been shown to increase the release
of met-enkephalin-like malerial in the spinal cord of anesthetized rats (LeBars et a/.•
1987), and high intensity stimulation of peripheral nerves and the intra-arterial
injection of bradykinin produces an enhanced release of met-enkephalin-like
material in the spinal perfusates of anesthetized cats (Yaksh and Elde, 1981).
Given the excitatory nature of o,..adrenoceplors in the eNS, and the rocation of
enkephalin~laining neurons in the dorsal hom, activation of these receptors could
facilitate the local release of enkephalin in the spinal cord.
Intracellular recordings indicate thai opioids induce a hyperpolarization of
neurons, secondary to an increase in K+ conductance (Williams et al., 1982;
Yoshimura and North, 1983). The relevance of these data to the antinociceptive
effect of opioids is indicated by the observation that: a) the elevated mouse lail-flick
latency induced by ~-, 6-, or K-agonists is attenuated by K+ channel blockers; and
b) antinocicepUon induced by K+ channel openers is blocked differentially by i.t.
opioid antagonists (norbinatlorphimine, lei 174,864, and naloxone) (Welch and
Dunlow, 1993). The results also suggest thai these two classes of drugs probably
do not interact al a common receptor, but rather with a common second messenger
system (Welch and Dunlow, 1993).
Opioid..jnduced hyperpolarization of dorsal hom neurons inhibits the release
of nociceptive neurotransmitters (see Figure 1). Thus, IJ-agonists have been shown
to inhibit the release of substance P in vivo (Yaksh et al., 1980; Kuraishi et 81., 1963;
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Go and Yaksh, 1987) and in vitro (Jessell and Iversen, 1977; Pang and Vasko,
1986). Substance P is a neurotransmitter found in small primary afferent fibers and
released by A61C.fiber activity (Yaksh at aI., 1980; Kuraishi et a/., 1983; see review
by Yaksh and Noueihed, 1985). Similarly, enkephalin-analogues (i.e. (j·agonists)
attenuate the evoked release of substance P in vitro (Jessen and Iversen, 1977;
Mudge at aI.• 1979) and in vivo (Go and Yaksh, 1987); an effect that is antagonized
by naloxone. Anatomical and electrophysioiogicsi dala also suggest thai opioids
can act at receptors localed post-synaptically to primary afferent terminals to
suppress nociceptive processing (see Figure 2) (see review by Yaksh and
Noueihed, 1985). D·A1a2·D·Lell-enkephalin (CADLE) attenuated glutamate-induced
excitation of attached rootlets in vitro (Zieglgi:lnsberger and Sutor, 1983), and
intracellular recordings in vitro showed thai application of morphine, DADlE, and
met-enkephalin results in hyperpolarization. These effects were antagonized by
naloxone. Additional evidence for a post-synaptic action of opioids has been
provided by recordings of cell bodies in the nucleus proprius following the
application of opioids near the terminals in the substantia gelatinosa. In particular,
morphine applied to the dorsal lamina has been shown to depress responses
evoked by noxious thermal stimuli, but has no effed ..men administered near the cell
body (see review by Yaksh, 1985).
These data indicate that enkephalin<.ontaining interneurons, and the opioid
receptOf's mediating their effect, are strategically located in the dorsal horn where
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Figure 2. Pre- and post-synaptic sites of antlnoclceptive action of oplold-
and a 2 -adrenerglc agonists In the dorsal hom of the spinal cord. The large
mangle represents a central nerve terminal of a small diameter, myelinated (AO) or
unmyelinated (C) primary afferent fiber from which substance P (SP) is released.
The large circle represents the soma of an adjacent second-order neuron in the pain
pathway which is activated (+) by substance P. The smalliriangies represent ~- and
~piojd receptors mediating the inhibitory (-) effects of morphine and enkephalin
(ENK), respectively. 02-AdrenocepIOfs, mediating the inhibitory effects of clonidine
or dexmedelomidine (OX). are indicated by the small squares.
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they normally modulate nociceptive transmission across the first synapse in the pain
pathway. By decreasing K· conductance, o,-adrenoceptor activation would bring
these neurons closer to the threshold for action potential generation thereby
facilitating the endogenous release of enkephalin under conditions of noxious
stimulation.
1.B AntlnocJcepUvelnteract;on Between Spinal a t- and Ql-Agonlsts In the
Rat· Oplold and Adrenergic Synergy
Previous studies in our laboratory have shown that a threshold dose of j,t.
methoxamine (10 I-IQ) potentiates the effect of i.t. dexmedelomidine (a2-saleclive
agonist) in the rat tal1-fllcl< and paw pressure tests (Loomis at al., 1992a, 1992b,
1993). Dexmedelomidine (0.01-1 1-19 i.t.) alone produced dose-dependenl
antinociception (ED50 =45 n9 in the tail-flick test and 252 ng in the paw pressure
lesl). The addition of a fixed dose of methoxamine (10 ",g i.I.), yielding <5% MPE
in the teil-flick lest and 0% MPE in the paw pressure test when injected alone,
significanlly shifted the dexmedelomidine dose response CUNe to the left (E050 =8.1
ng; tail-flick test and 10 ng; paw pressure test). Methoxamine did not prolong
dexmedetomidine's duration of action suggesting that a pharmacoklnetic interaction
was unlikely. Moreover, pretreatment with SCH 32615 (75 I-Ig Lt.; a neulral
endopeptidase inhibitor), but not vehicle, produced a further parallel leftward shift
of the methoxamine +dexmedelomidine dose response CUNe (ED50 =1.8 ng; lail-
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flick test and 7.7 ng; paw pressure Illst). This potency shift exceeded the effect of
SCH 32615 on dexmedetomidine alone. A fIXed dose c:ombinatlon of methoxamine
(10 1J9) +dexmedetomcfine (0.025 1J9), producing near maximal activity in the lail~
flick test a1d intennediale activity in the paw pr8SSl1'8 test, was significantly blocked
by each of the following pretreatments: pra20sin (10 1'91.1.), WY 27127 (0.51'9 i.I.),
naloxone (30~ l.t.), ICI174,864 (75lJQ1kg I.p.), and antiserum to Met-enkephalin
(10 ~I Lt.). These data strongly suggest that the synergy exhibited between MX and
OX involves a spinal enkephalin-dependent process, consistent with the known
antinociceptiv8 synergy between spinal oploid- and 02-agonlsts in experimental
animals (Ossipov et al., 1990; Omote at ai" 1991; Roerig at ai" 1992), and in
humans (Molsch at al., 1990; Gordon at a/., 1992; Siddall at al., 1994). The
interaction desalbed between a-agonists is not specific to MX and ox.. Intrathecal
NE-induced anlinociception in the rat was also potentiated by SCH 32615, and
antagonized by i.t naltrindole (6-selective antagonist) or i.t naloxone (loomis et al.,
1993). Thus, a,-adrenoceptors may be CX)fllribute to spinal adrenergic
antinociception by facilitating the local enkephalinergie-modulation of nociceptive
transmission (Figure 1).
1.9 Rationale, Research Hypothesis and Specific Objectives
There is an extensive and cons;~.:·'mt body of evidence indicating that a2•
adrenoceptOl" mediated anlinociception is a direct and selective inhibitory effect on
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relevant sensory neurons in the spinal cord that is independent of endogenous
opioid systems. The phannacological activation of spinal 0l·adrenoceplors effects
antinocicepUon in experimental animals. However, these receptor sUbtypes are
nonnally excitatory in the eNS suggesting that their ability 10 interrupt nociceptive
transmission in the spinal cord must involve the activation or facilitation of an
inhibitory neural input. Considering the dense localization of enkephalinergic
interneurons in the dorsal hom, the selective modulatory effect Clf enkephalin on
nociception in the spinal cord, and the well characterized antinocicepliv9 interaction
between opioid- and 02-agonists in the spinal cord of experimental animals, we
hypothesized that spinal a,..adrenoceptors facilitate the release of enkephatin in the
rat spinal cord. The observation that i.t. methoxamine significanlly potentiated the
inhibitory effect of Lt. DX in thermal and mechanical nociceptive tests via an
enkephalin-dependent process provides further support for such a mechanism.
If this hypothesis is correct, then non-selective a-agonists (Le. those with
affinity for both a,- and a 2-adrenoceptors), given i.t. to the rat, should exhibit
antinociceplive aoss·tolerance to i.1. 6-selective agonists. Thai is, down-regulation
of spinal 6--opioid receptors following the continuous i.t. infusion of a 6·selective
agonist (Le. DAOlE) should allenuate the hypothesized enkephalinergic mechanism
underlying aI-mediated antinociception in the spinal cord (see Figure 1). In
contrast, a 2-seleclive agonists (e.g. OX), that do not utilize an enkephalin-dependenl
mechanism, should exhibit no such cross-tolerance (Figure 1).
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To test this hypothesis, male Sprague-Dawley rats were continuously infused
with either morphine (~-agonjst). D-A1a2~O-lelf enkephalin (CADLE; highly specific
6-agonist) or vehicle for 6 days using ALZET osmotic mini..pumps. Infusion doses
producing robust antinociception via distinct spinal opioid sites (~versus 6) were
verified with ~. and ~seleclive antagonists. Antinociceplion was determined during
and after infusion using the tall-flick test. Mer the G-day infusion was discontinued.
dose-responsa curves for Lt. NE (non-selective a-agonisl) or OX were determined
in morphine-tolerant, CADLE-tolerant and vehicle-infused rats. The magnitude of
cross-tolerance was delennined from the shift in the dose-response curve (e.g. E050
potency ralio). The specific otl.. I'-::,.ives of the thesis research were:
1. To determine the lime.course of recovery of antinociceptive activity following
the continuous i.I infusion of morphine or DADlE.
2. To determine if rats, made toleranllo LI. morphine, exhibit antinociceplive
cross·tolerance 10 Lt. NE.
3. To determine if rals, made toterant to U. CADLE, exhibit antinociceptive
cross-tolerance to Lt. NE.
4. To determine if rats, made toterant to i.t. DADLE, exhibit antinociceptive
cross·tolerance 10 i.t. OX.
,.
5. To verify the selectivity of i.t. OX for 02-adrenoceptors by comparing its
!snsitivity to the 02-antagonist, WV 27127, and the a,·anlagonist, prazosin.
6. To verify the selectivity of morphine and DAOLE for IJ- and O-receptors,
respectively, during continuous i.t. infusion by comparing their sensitivity to
the 6~antagonist, naltrindole, and the IJ-antagonist, naloxone.
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2.0 METHODS AND MATERIALS
1.1 Anlm_/s
All procedures were approved by lhe Animal Care Committee of Memorial
University in accordance with the Guidelines of the Canadian Council on Animal
Care. Male, Sprague-Dawley rals (Charles River Canada, 81. Constant, Canada)
weighing 250·350 g were used for aU experiments. Animals were housed In 6
climate controlled room with a 12 hour Iighl-dark cycle (lights on at 07:00 h). Tap
water and rodent laboratory chow were freely p·ovided. Animals were housed
Individually and allowed a 2~ days acclimatization period before use.
2.2 Gen.,./Methods
The general axperimeotal profoc:o{, consisting of the surgical implantation of
I.t catheters. baseline testing, continuous j.t infusion via osmotic mini-pumps, and
termlnation of the Infusion with removal of the mini·pumps, is shown in Figure 2.
2.2. f Int,.'hec.1 C.theter Implantation
Rats were anesthetized with halothane (Halocarbon Laboratories, River
Edge, N.J.) and implanted with 1.1. catheters using the method ofYaksh and Rudy
(1976&), 85 modified by loomis et al. (1987b). AIII.t. catheters were constructed
from PE10 tubing. A permanent loop was made in the catheter for attachment to the
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Figure 3. The general protocol for experiments using continuous 1.1. Infusion.
,.
surrounding musculature and the tubing was cut 7.5 em distal to the loop. The
proximal end of the catheter was connected to a piece of PE 60 tubing (3 em in
length) and the junction was fused with heat. The larger tubing was used as an
adaptor 10 connect the i.t. calhf·'.Nto an osmotic mini-pump (ALZET 2001; ALZA
Corporation, Palo Alto, USA) for continuous i.t. drug infusion. After filling the
catheter-adaptor assembly with nonnal saline. the i.1. catheter was inserted through
a small slit in the cisternal membrane, and carefully guided through the spinal
subarachnoid space so that the tip was positioned near the lumbar enlargement.
The catheter loop was sulured to the overlying muscle and the delivery system was
flushed with normal saline. The lip of the PE 60 adaptor was heated with a
soldering iron and pinched to seal the end. The adaptor was then inserted into a
subcutaneous pocket on the back of the animal, the incision was closed with 3-4
sutures and the animal was allowed 10 recover for at least 4 days. Only animals
exhibiting normal motor function and having normal baseline responses in the tait-
flick tost (D'Amour and Smith, 1941) were used for experimentation.
2.2.2 Osmotic Pump Preparation and Implantation
One day prior to pump implantation, each osmotic mini-pump was filled with
freshly prepared drug solution or vehicle (see belOVo') and incubated in normal saline
at room tem:erature overnight. On the following day, the pumps were transferred
to a waler bath and heated to 37°C 2-5 h before surgery.
,.
Animals, previously implanted with lot. catheters, were anesthetized with
halothane. An incision was made in the skin overtying the S.c. pocket thai contained
the PE 60 adaptor and the tip was ex1emalized. The sealed tip was cut with
scissors. the catheter-adaptor assembly was flushed with 20 ~I of normal sal,., and
the adaptor was trimmed to a final length of about 7 mm. The obturator of the
osmotic punp was fitted directly into the PE 60 adaptor a..,d the pump was inserted
into the s.c. pouch. The wound was then closed with sulures and the animals were
allowed to recover overnight. The combined dead volume of the Lt catheter and the
trimmed adaptor was 10.6 ± 0.31J1 (mean ± SO; n = 28).
2.2.3 Continuous Inltalhecallnfusion
Animals received either morphine sulfate (5, 10 or 20 lJ9·h·'), [D-A:.f O.leu't
enkephalin (CADLE; 10 ~g·h·tl or saline (1 1J'·h-l) by continuous i.t. infusion for 6
days. Tail-flick latency was determined daily between 08:00 and 10:00 h to
minimize the effects of diurnal variation on behavioral responses (Frederickson et
a/., 1977). Bod)' weight was also recorded dally and room temperature was
maintained between 23-25°C. Immediately after testing on day 6, the animals were
lightly anesthetized with halothane and an incision was made in the skin overlying
the mini-pump. The pump-adaptor assembly was removed from the s.c. pocket and
cut near the catheter-adaptor junction with scissors. The rostral end of the catheter
was passed s.c. to the back of the head, externalized through the skin, and the
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incision was closed with sutures. The catheter, having a dead volume of 7.9 ± 0.21.11
(n=47), was flushed with 101.11 of sterile saline 10 clear the residual drug solution,
except for rals infused with morphine (20 ~g·h·'). In thIs case, the catheter was
initially flushed with 51.11 of saline followed approximately 0.5 h later with another 10
1-'1 of saline 10 clear the remaining drug solution. Two separate saline flushes,
spaced 0.5 h apart, were necessary to minimize the development of high dose
morphine hyperesthesia (Yaksh at <JI., 1986; Stevens et a/., 1988; Slevens and
Yaksh, 1992). The catheters was sealed with a stainless steel plug and used for
alt subsequent U. drug injections. The animals were allowed to recover overnight
before being assigned 10 either: A) the opioid·recovery experiments; or B) the
cross·tolerance experiments.
2.2.4 Recovery from Oploid Tolerance
To determine the timEH:OUrse of recovery from morphine tolerance, animals
were infused with i.t. saline (1 lJI·h·1) or morphine (5 IJg'h") for 6 days. The infusion
was terminated (as described above) and a test dose of i.t. morphine (4I-1g) was
injed.ed beginning on day 1 post-infusion. The test dose of morphine was chosen
from previous dose-response experiments to yield a near maximal effect in the tail
flick test. To minimize the possibility of prolonging opioid tolerance with repealed
test doses of i.t morphine, each rat received only one test dose during the recovery
period (days 1-5 post·jnfusion). Thus, separate groups of rats were used for each
J2
of the 5 post-infusion days. A similar protOCOl was used 10 determine the time·
COlSSe ctrecov8lYfoI1owi'lg contirlJOUS i.t DADLE infusion (10 J,Jg'h"), except that
a test c:Ioseof3 IJ5ldi.l OADLEwasused. In another group d morphine {5~'h'1}­
and saline (1 ~-tfl}-infused .-ats, dosEH'"esponse curves of i.t morphine were
determined in the post-infusion period. The E050 ratio was then calculated to
quantitate the magnitude of opiold tolerance.
2.2.5 Crossp Tolerance Experiments
The magnitude of cross-tolerance between opiofds and a-agonists was
determined using cIose-response analysis. In morphine-tolerant rals, lest doses of
NE (2.5,5.0, or 10 1J9 i,t) were injected on days 1-3 posl-lnfusion. In CADlE-
tolerant rats. test doses ofNE orOX( 0.1, 0.2,0.3 and 0.5 ~ i.t.) were injected on
days 1-2 post-infusion. These time porns were chosen from CMX study of the
recovery from morphine and CADLE tolerance. All behavioral testing was
ca"lducted between 08:00 and 14:00 h. Rals received only one i.t dose of NE or
OX per day. Tail·fIick latencles were meaSl.led immediately before and 30, 50, and
90 min after injection of the test dose of NE or OX. Body weIght was recorded daily
throughout the cross-tolerance experiments.
2.2.0 a·Antagonlst experiments
Separate groups of rats were surgically implanted with 1.1 catheters 8S
J3
described above, except that no PE 60 adapter was used. Rather, the s.c. end of
the catheter was externalized on the back of the head and sealed with a stainless
sleel plug. The dead volume of the catheter was 7.0 ±0.8 IJI (n=46). The selectivity
of Lt. OX (0.5 ~) for a 2-adrenoceplors was assessed by challenging the agonist
with i.t Wyeth 27127 (WY; Qz-selective antagonist) or prazosin (PZ; oj-antagonist).
Tail flick lateneles were initially measured before and 15 min after i.l. OX.
Immediately following this 15-min determination, rats were given a second i.t.
injection of either WY (101-19), PZ (101-19), or vehicle (OMSO or saline). Tail flick
latencies were then determined 30.45. and 60 minutes after OX administration. As
Ihese experiments required two U. injecllcns spaced .. 15 min apart, \NY and PZ
were injected in a volume of 5 !JI, followed by 10 IJI of saline.
2.2.7 Oploid Anfagonlsl Experiments
The selectivity of morphine and DADLE for IJ- and 6-receptors during
continuous Ll infusion was assessed by challenging each agonist with naloxone (1
mglkg i.p.) or naltrinctole (1 mglkg Lp.; determined from previous experiments). Rats
were continuously infused with morphine (20 ~g'h-l) or DADlE (10 IJg·h·1) as
described above. Naloxone or naltrindole was injected on day 1 of infusion (i.e.
when anlirlociceplion was maximal) in a volume not exceeding 0.2 ml for naloxone
and 0.5 ml for naltrindole. Tail flick latency was measured before, and 15, 30, 45,
50, ancl 00 min after i.p. administralion. FOf graphical purposes, data from each rat
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were calOJlaled as the %of the peak tail flick lalency to correct for the difference in
maximum antinociception induced by morphine and DADlE. However, all statistical
analysis was conducted on the raw dala.
2.2.8 VerlflcaUon ofClltheterPosltion
At the completion of each experiment, animals were injed.ed with 10 ~I of 5%
lidocaine followed by 10 ~I of saline. Rats were subsequently obselVed for evidence
of hind limb weakness Of paralysis, indicative of the correct placement of the spinal
catheter. A laminectomy was also performed on rats randomly selected from the
experimental groups 10 visually confirm the position of the catheter.
2.3 Drugs
Morphine sulfate (BOH Chemicals, Toronto, Canada) or [D-Ala2, D-teu!}-
enkephalin (Acetate Salt, Sigma Chemical Company, St.LoUis, USA) was dissolved
in 0.9% saline, These solutions were filtered through a sterile MiHex-GS filter (0.22
~m; Millipore Products, Bedford, USA) as the osmotic mini-pumps were filled.
Norepinephrine bitartrate (Sigma Chemical Company, SI. louis, USA),
dexmedetomidine Hel (Orion Corp. Farmos, Turku, Finland), WY 27127 HCI (Wyeth
Ltd., Philadelphia, USA), naloxone HCI (Research Biochemicals Incorporated,
Natick, MA), naltrindole HCI (Research Biochemicals Incorporated) and lidocaine
HCI (Sigma Chemical Company) were dissolved in 0.9% sterile saline. Prazosin
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Hel (Sigma Chemical Company) was dissolved in dimethyl sulphoxide (OMSO,
98%; BOH Chemicals, Toronto, Canada). Drug solutions were freshly prepared on
the moming of the experiment, except lidocaine which was stored al46 C for up to
2 weeks. Except where indicated, all drugs were infected Lt.ln a volume of 10 IJI
followed by 10 IJI of saline using a hand held IJI-syringe. All doses are expressed
aslhe sail.
2." Aigesiometrk resting and Data Analysis
Tail flick latency was measured using a Tail FUck Analgesia Meier, model
MK-330 (Muromachl Kika! Co. ltd.• Tokyo, Japan); acut-off of 10 s was imposed
to avoid tissue damage. All data are expressed as the mean ± the standard error
of the mean (SEM). For the cross-tolerance experiments, dala were analyzed as
both absolute tail flick latency (sec) and as the maximum percent effect (MPE).
MPE was calculated using the equation:
post drug response· predrug response
MPE= X 100
cutoff ~ predrug response
MPE values below baseline were assigned an MPE of zero (Russell et ai, 1987).
Area under the tail flick latency versus lime curve (AUC) for each rat was calculated
by trapezoidal approximation.
DoslH8sponse analysis, including the EDso and 95% CI, the least-squares
regression lile, and lests for parallel shifts of dose-response aJrves, were based on
"
the methods outlined in Tallarida and Murray (1987). ED~'s and 95% el's were
calculated using both peak tail flick latencies (where the EOso is the midpoint of the
regression line extending from the mean control base;ine 10 the 10 5 cut~ff), and
MPE's (where ED50=50% MPE). EDso ratios were defined as the ED50 of the test
drug in opioid·irtused animals divided by the corresponding ED!IO in saline-Infused
rats (ED60 (opiold)'EOeo (saliner11. A signifICant difference between two groups was
determined using either the unpared Student's Hest or Mann·Whitney two-sample
lesl Repeated measures, one-way ANOVA was used to analyze the within-group
time-colrse data; completely randomized, one-way ANQVA was used for all other
multiple group comparisons. Posl-hoc analysis was performed using the Newman-
Keuls test and differences with a probability of P<O.05 were considered statistically
significant. A significant shift in the ED50 of NE or OX in opioid- versus saline-
infused rats was indicated when the 95% el's did not overlap. Oala were recorded
and analyzed using a commercial spread·sheet program (Ouattro Pro) on a Wise
Data System computer. Statistical analyses were conduced using a commercial
program (Instat).
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3.0 RESULTS
3.1 NlorphlneExperiments.
3.1.1 Induction ofMorphine Tolerance with Continuous Intrathec.llnfusion
Spinal morphine (5, 10 and 20 ~g·h·') induced significanl antinociception as
compared to sa1ine~jnfused rats on days 1 102 of infusion (Figure 4). Tail-flick
latency peaked on day 1 and then progressively declined 10 baseline over the next
5 days. The area under the curve (AUC) for each morphine infusion dose was also
significantly different from saline (data not shown), confirming the antinociceptive
effect. Saline had no effect on tail-nick latency throughoullhe infusion period. A
parallel, rightward shift in the morphine dOS8-fesponse curve, representing a 6-fold
incl'Elase in the ED". was observed on day 1post·jnfusion in rats that had received
morphine (5 ~g'h") for 6 days. The E050 and 95% CI of I. 1. morphine was 1.02 1J9
(0.87-1.20) in the saline-infused group and 6.22 j.Jg (4.76-7.99) in the morphine-
infused group. These data are consistent with the induction of morphine tolerance
following continuous 1.1. morphine infusion.
3.1.2 Behavlora/Effects with Morphine Infusion
The general behaviour of rats appeared 10 be unaffected during morphine or
saline infusion. Morphine-treated rals, especially those receiving 20 j.Jg·h·\ exhibited
increased muscle tone in the hind limbs and stiff tails on the first day of infusion.
Generally, these effects disappeared by the next morning and were not observed
Ja
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Figure 4. The time coune of tall·fllck latency during the continuous I.t.
infullon of: A) morphine 5 vg·h"; C) morphine 10 fl9-h"; or 0) morphine 20
JIg'h't for 6 days. Control animals received continuous i.t. saline (11J1'h'l). Each
poinl represents the mean ± SEM of 6-16 morphine-treated and 4-1 a saline-trealed
rats, All points were significantly different from saline control on days 1 and 2,
except morphine (10 lJQ'h'l) on day 2 (Sludent's 1·lest or Mann·Whitney two sample
test; A:. *,*P<O,OO5; '.fP<O.05; B: *,*P<O.OO5; 0: flP<O.OOOS; *P<O,OO5). AUC's
for opioid infused animals \N8re signifiCMtly different from saline (Mann-YVhitney two
sample test;P<O.OS). B): Morphine dose-response curves determined one-day
after the saline or morphine (51J9'h") infusion had been discontinued. The ED50
and 95% CI of 1.1. morphine was 1.02~ (0.87-1.20) in saline-infused rats and 6.22
IJg (4.76-7.99) in lllOl'phine-infused rats.
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thereafter. The highest dose of morphine (20 IJg·h·1) produced hematuria in two
rals. All groups displayed 8 comparable inaease in body weight during the infusion
period (days 1-8; Figure 5), indicating thai 100 i.t. catheter and s.c. osmotic pump
were weilioleraled.
After removal of the pumps on day 6, some morphine-infused rats exhibited
signs of opioid withdrawal. Diarrhea, piloerection, sensillvity to touch and increased
vocalization upon handling were observed on day 1 post-infusion. A significant
deaease in body weight was also observed after the morphine-infusion had been
discontinued (as compared to saline-Infused rats; Figure 5). This deCfoase was: a)
maximal on day 1 post-infusion and coincided with the appearance of opioid
withdrawal behaviour; b) opioid dose-dependenl; and c) temporary, with animals
regaining their body weight 4 days alter terminating the infusion (data not shown).
Following removal of the pump and subsequent flushing of the i.t. catheter with
saline, 52% of animals (7 of 15) receiving morphine (20 IJg·h·l ) displayed a transient
writhing, biling and scratching of the dermalomes, suggestive of hyperesthesia.
3.1.3 Recovery from Morphine Tolerance
To delennine the lime course of recovery from tolerance following low dose
(5 Wh01)-morphine infusion, a probe dose of morphine (4 ~g i.t.) was tested once
daily during the post-infusion period (Figure 6). Aller saline-infusion, morphine
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Figure 5. l'he change In body weight during (days 1-61 and after (day. 7-9) the
continuous I.t Infusion of: A) morphine (5 1J9'h'll or ullne (1 JoII·h·'); B)
morphine (10 lJ9·h·l ) or saline; and C) morphine (20 IJg·h·' ) or ••Ilne. Data are
expressed as the percent of body weight before infusion and each point represents
the mean ± SEM of 4·10 saline-infused and 6·16 morphine-Infused rats. Symbols
indicate a significant difference from saline-infused rals at the corresponding time
point (unpaired Student's t-test or Mann-'Nhitney two-sample lest, where applicable;
+P<O.OO01; ,**P<O,OO5; ,*P<O.OS).
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Figure 6. The time course ofrecovery from morphine tolerance following the
continuous I.llnfuslon of morphine (5 IJg·h"l) for 6 d!!ys. Histograms indicate
the maximum tail-flick response to a test dose of morphIne (41Jg i.t.), injected on
consecutive days after the infusion was discontinued. Separate groups of rats were
used on each post-infusion day and the results represent the mean ± SEM of 6-1
rats. The results are also expressed as a percent of the morphine effect In saline·
jnfused rats. The upper solid horizonlalline and adjacent dashed Jines represent
the maximum tail.flick latency:t SEM produced by the morphine test dose in saline-
infused rats (n=23). The lower solid line and adjacent dashed Unes indicate the
baseline response :t SEM before injection of the test dose. An asterisk denotes a
significant difference from saline·infusad animals (one-way ANOVA followed by
Newman·Keuls test; P<O.OS). Significant recovery from tolerance was nolobserved
until day 4 post·infusion.
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produced an average taif·flick latency of 9.1 ±0.3 s (n = 23),determinecl over a 14-
day post-lnlusion period (see upper horizonlal1ine and adjacent dashed Iill9s in
Figure 6). The same test dose had a minimal effect in morphine-infused rats up to
day 3 post·infusion (n=6-7). Partial recovery from morphine tolerance was observed
on day 4 post-infusion (76.8% of morphine activity in saline-infused rats), and by day
5, recov9f)'wss complete (95. 1% of morphine activity in saline-infused rats). lhasa
results indicate that i," infused animals remain significantly tolerant 10 the
anlinociceptive effect of morphine three days alter morphine is discontinued.
Acrordingly, cross-tolerance experiments with i.t. NE were conducted on days 1-3
post·infusion.
3.1.4 Cross~ Tolerance $ludles between Morphine and NE
The time course or tail-flick latency following the acute i.l. injection of NE
(2.5, 5.0 and 10 1-19) in rats thai been infused with morphine (5 IJg·h·t) or saline (1
I.Ilfl'l) are shown In Figure 7, AU doses of NE significantly increased tail-nick latency
in both treatment groups, Peak antinociception occurred 30 min after injection, with
tail.flick latency reluming to baseline 60 min after the 2.5- and 5.0·~ doses, and 90
min after the 1O-lJg dose, AUC analysis of the NE time-course data indicated no
significant differences between the morphine- and saline-infused groups (Table I),
except for NE (2.5 and 10 I-Ig) in morphine {10 IJg·h,IHnfused rats. Both doses
produced amarginally but significantly lower antinociceptive effect in this morphine-
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TABLE I. Summary of the Differences in the Area Under the Tail-Flick latency
versus Time Curve (AUC) Following the Intrathecal Injection of
Norepinephrine (NE) in Rats Previously Infused with Morphine Of
Saline for 6 Days
NE DOSE (~g) TREATMENT (dose) AUC (s'min)
2.5 SALINE (1 ~I·h·') 315:t54
MORPHINE (5 ~g'h") 274 ± 27
5.0 SALINE (1 ~I.h·') 399.28
MORPHINE (5 1-l9·h·1) 385:t 24
10 SALINE (1 ~I·h·') 579.35
MORPHINE (5 ~g·h·') 504 ± 32
2.5 SALINE (1 IJI·h·1) 329 ± 20
MORPHINE (10 ~g·h·') 200t 13*
5.0 SALINE (1 ~I·h·') 406:t41
MORPHINE (10 ~g·h·') 354:t 22
10 SALINE (1 ~I'h") 573.42
MORPHINE (10 ~g'h") 448:t3D*
2.5 SALINE (1 ~I·h·') 343.28
MORPHINE (20 ~g'h") 314.13
5.0 SALINE (1 ~1·h·'1 402:t 30
MORPHINE (20 ~g·h·') 379:t 24
10 SALINE (1 ~I'h") 559:1: 40
MORPHINE (20 ~g·h·'1 492:t31
'* P<O.OS
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Figure 7. The time course of tail·f1ick lalency following the acute 1.1. Injection
of NE: A) 2.5 1-19: B) 5.0 1-19; and C) 10 1019 to rats previously Infused with
morphine (5IJg'h'l; .A.) or saline (1 1J1·h-'; .). Dala are expressed as the mean
± SEM of 10 saline-and 15 morphine-infused rats, except Figure 7A where n = 4
and 6, respectively. Doses of NE were injected on days 1-3 post-infusion. There
were no significant differences between the two groups except at time 0 (baseline)
in Figure 78 (unpaired Student's t-Iest or Mann-Whitney two-sample lesl, where
applicable; '* P<O.01).
45
infused group (Table I). Identical NE time course studies were conducted following
the continuous &day infusion of i.t. morphine (10 and 20 1J9'h") and saline (1 Ill-h")
(data not shoYm). Using the peak lail·f1ick response (30 min) from these dala, NE
dose-response aJrve8 were constructed (Figures 8-1 0). Regardless of the infusion
rale, there was no significant shift in the NE dose-response curve in morphine-
tolerant as compared to saline·infused animals. The dose-response curves did not
differ from parallelism (P>O.05) and the EOso's of Lt. NE were comparable in bolh
treatment groups (overlapping 95% CI's; Table II). The EDso ratio was 1.12, 1.51,
and 1.35 fcrlhe 5-, 10- and 20-1J9·h" infusion dose, respectively (Table II). These
data indicate that there was no significant cross-tolerance between i.t. NE and
morphine in the rat tail-flick test at morphine infusion rates up to 20 Ilg·h·1 for 6 days.
3.2 DADLE Experiments
3.2.1 Induction ofDADLE Tolerance with Continuous Intrathecal Infusion
The time-«lUrse of tail-flick latency during the continuous infusion of DADLE
(10 jJ9·h·') or saline (1 Ill-h") is depicted in Figure 11. Like morphine, significant
antinociception was observed on days 1 and 2 of infusion (P<0.05). The AUC for
the DADLE-infused group was also statistically different from that of saline (P<O.05).
Peak tail-flick latency occurred on day 1 and then gradually declined to baseline on
day 3. reflecting the development of opioid tolerance in the spinal cord.
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Figure SA. NE doae-response curves (expressed as peak tall·nlck latency In
seconds) determined after the continuous I.t. infusion of saline (1 fjI·h": .) or
morphine (5 ~·h·'j A) for 6 days. NE was lested on days 1·3 post·infus;on with
only one dose injaded daily. Cala are expressed as the mean ± SEM of 4-15 rats.
The corresponding EOso (95% el) of i.I. NE, expressed in IJg, is indicated on the
figure.
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Figure 8B. NE dose-response curves (expressed as MPE) detennlned after the
continuous I.t.lnfuslon of saline (1 ..-I·h"; _, or morphine (5 Jlg·h"; A) for 8
days. NE was tested on days 1-3 posl-infusion with only one dose inj!\lcted daily.
Data are expl'essed as the mean ± SEM or 4·15 rats. The corresponding EDso (95%
el) of I.t. NE, expressed in 1-19, is indicated on the figure.
47
21---~--~--~--
2 3 5 7 10
I.T. Norepinephrine (pg)
FIgure gAo NE dose-r.sponse curves (expressed as peak tall·fllck latency In
seconds) delennined after the continuous I.t. infusion of saline (1 tJI·h'l; .) or
morphine (10 ~·h·1; A) for 6 days. NE was tested on days 1-3 posl·infusion with
only one dose injected daify. Oala are expressed as the mean ± SEM of 5~9 rats.
The corresponding EDeo (95% el) of i.t. NE, expressed in 1J9, is indicated on the
figure.
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Figure 98. NE dO......apon•• curves (expressed as MPE) determined Ifter the
contlnuoual.t. Infusion of saline (1 pl_h'l; .) or morphine (10 PO·h,l j A) for 6
clap. NE was tested on days 1-3 post-infusion with only one dose injected daily.
Data 8(8 expressed as the mean ± SEM of 5-9 rats. The corresponding ED!ll) (95%
el) of Lt. NE, expressed in 1J9, is indicated on the figure.
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Figure i0A. HE doae~sponse curves (expressed as peak tall·fllck 'atency In
seconds) determined after the continuous I.t. infusion of saline (11A1·h"; .) or
morphine (20 lJO'h'l; .&) for 6 days. NE was tested on days 1-3 post·infusion with
only one dose injected daily. Data are expressed as the mean t SEM of 7-14 rats.
The corresponding EOso (95% el) of Ll. NE, expressed in ~g, is indicated on the
figure.
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Figure 108. HE dose.,.e.ponse curves (expressed as MPE) determined after
the continuouaU.lnfuslon of saline (1 ~l'h"; .) or morphine (20 JolU'h"; .A.) 'or
8 days. NE was tested on days 1-3 post-infusion with only one dose injected daily.
Data are expressed as the mean ±SEM of 7-14 rats. The corresponding EDso (95%
CI) of Lt. NE, expressed in ~g, is indicated on the figure.
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TABLE II. EDso, 95% Confidence Interval eel) and ED50 Ratio for Intrathecal
Norepinephrine Following the Continuous Intrathecal Infusion of
Saline or Morpnine
TREATMENT (dos.) EDso (95% CW EDso Ralio~
SALINE (1~I'h") 4.33 ~g (3.10-6.05)
MORPHINE (5 ~g·h·') 4.84 ~g (3.77-6.22) 1.12
SALINE (1 ~I·h·') 3.72 ~g (2.54-5.44)
MORPHINE (10 ~g·h·') 5.60 ~g (4.63-6.77) 1.51
SALINE (1~I·h·') 4.70 ~g (3.52-6.29)
MORPHINE (20 ~g'h") 6.35 ~g (5.14-7.85) 1.35
a EDso and 95% CI calculated using MPE data
b EDso ratio is defined as E050 in opioid·infused rats·EDso in saUne-infused rats-l
No significant differences (P>O.05)
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Figure 11. The tlme-course of tail-flick latency during the conlinuous !.t.
Infusion of CADLE (10 foIg·h·1) or saline (1 ..J1·h·1). Dala are expressed as the
mean ± SEM of 7-21 rals and the asterisks denote a significant difference between
the DADLE and saline groups (Student's t-last or Mann-Whitney two sample test,
**P<O.OO5; *P<O.05).
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3.2.2 Seh.vlofll Effects with DADLE
All animals exhibited normal grooming and feeding behaviour throughout the
Lt. infusion period; both CADLE- and saline-treated rats had comparable increases
in body weight on days 1-6 (Figure 12). Forty percent of CADLE-infused rats (8 of
20) exhibited stiff tails on day 1 of infusion. When the pumps were removed at the
end of the infusion period and the i. 1. catheters were flushed with saline, 65% of
OADLE-infused rats (40 of 61), but no saline-infused rals, displayed a cataleptic
condition for up 10 1 h. These animals had muscular rigidity and could be easily
manipulated into an upright "silting" position where they remained stationary until
moved by the observer. There was no startle response and no effort to escape.
CADLE-infused rats also exhibited a significant decrease in body weight as
compared to control in the immediate post-infusion period (Figure 12), indicative of
opioid-withdrawaL Collectively, these data are consistent with the continuous spinal
infusion of DADLE and indicate that the decline in antinociceptiv8 activity was not
due to a problem with the drug delivery system (LI. catheter and/or osmotic pump).
3.2.3 Recovery from DAOLE Tolerance
The time-<:ourse of recovery from OADLE tolerance is shown in Figure 13.
The DADLE test dose (3-~g Lt.) significantly increased tail-flick latency in saline-
infused animals on days 1-4 post-infusion, yielding a mean peak effect of 9.5 ± 0.4
s (upper solid horizontal and adjacent dashed lines). In OADLE-tolerant rats, the
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F~ure 12. The change In body weight during (days 1-6jand aft.r(day. 7"")
the contlnuous I.l Infusion of DADLE (10 ~g'h") or saline (1 tll,h"). Each point
represents the meantSEM of 7-21 rats and the asterisks indicate a significant
difference between the saline and CADLE groups (unpaired Student's t-test or
Mann·Whitney two-sample test, where applicable; **P<O.005; ,*P<O.05).
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Figure 13. The time cours. of recovery from OADLE toleranc. following the
continuousl.llnfulion of DADLE 110 ~g·h·l) for 6 days. Histograms indicate the
maximum tail-flick response to a lest dose of CADLE (3 JJQ i.t.), injected on
consecutive days after the infusion was discontinued. Separate groups of rals wefe
used on each post-infusion day and the results represent the mean ± SEM of 4-5
rals, except on day 4 where n =3. The results are also expressed as a percent of
the CADLE effect in salino..-infused rats. The upper solid horizontal line and adjacent
dashed lines represent the maximum tail-flick latency ± SEM produced by the
DADlE lest dose in saline-infused rats (n=13). The lower solid line and adjacent
dashed lines indicate the baseline response ± SEM before injection of the test dose.
Asterisks denote a significant difference from saline-infused animals (unpaired
Student's t·tast or Mann-Whitney two sample test, where applicable,**P<O.OOO1;
'*P<O.005). Significant recovery from tolerance was observed on day 3 post-
infusion.
5.
same test dose had little anlinociceptive activity on days 1 and 2 post-infusion.
Peak tail-flick latency was only 7.1 % and 16.0%, respectively, of that induced by
CADLE in the salifl&.infused group. By day 3 post-infusion, this effect increased 10
81.5% (8.4 ± 1.1 s) and recovery of anlinocicepliv8 activity was virtually complete
(00.2%) by day 4 post-infusion. Accordingly, cross-tolerance experiments to DADLE
were conducted on days 1-2 post-infusion.
3.2.4 Cross-Tolerance Studies between DADLE and NE
AUC analysis of the time-course profiles for individual test doses of Lt. NE
(see Figure 14) revealed a significant reduction in anlinociceptive activity in rats
previously infused with CADLE (10 IJg·h·1) as compared to saline (Table III). This
attenuated response was confirmed by the rightward displacement of the NE dose·
response curve in OADlE-tolerant rats (Figure 14) and the corresponding increase
in the E050 of NE (ED50 ralio was 2.54; Table IV). The dose-response curves did not
differ from parallelism (P>O.05). Thus, rats made lolerant to DAOlE using
continuous Ll infusion for 6 days displayed significant cross-tolerance to Lt. NE in
the post-infusion period. For completeness, NE dose-response curves were
analyzed as both the absolute latency (s) and as MPE. There was no difference
in the overall result using either method of calculation.
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Figure 14. The time course of tall·tUck latency following the acute I.t. Injection
of NE (5.0 Jig) to rata previously Infused with CADLE (10 tJg·h-1j .) or saline (1
.,'·h·' j .). Dala are expressed as the mean ± SEM of 7 saline- and 12 DADLE-
infused rats. Asterisks indicate a significant difference between the two groups
(unpaired Studenfs t·test or Mann-\Nhitney two-sample test, where applicable; **
P<O.OOO1; ·*P<O,OS).
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TABLE III. Sumwyctthe Differences in the Area Under the Tail-Flick latency
versus Time Curve (AUC) Following the Intrathecal Injection of
Norepineptyine (NE) n Rats Previously Infused with OADlE or Saline
for 6 Days
NEOOSE (~g)
2.5
5.0
10
TREATMENT (dose)
SALINE (1 ~I·h·')
OAOLE (10 ~·h·')
SALINE (1 ~I·h·')
OAOLE (10 ~g·h·')
SALINE (1 ~I·h·')
OAOLE (10 ~g·h·')
AUC(s-min)
377 t 29
302 ± 6*
503 >27
327 ± 17t
617 ± 36
434 :1:24**
.. P<O.05; ** P<O.OO5; t P<O.OOO1
TABLE IV. EOso• 95% Confidence Interval (el) and EOso Ratio for Intrathecal
Norepinephrine Following the Continuous Intrathecal Infusion of
Saline or CADLE.
TREATMENT (dose)
SALINE (1~I·h·')
OAOLE (10 ~·h·')
EO,,(9S%CI)
2.64 ~g (1.56-4.48)
6.70 ~g (S.OS-8.as)
EDsoRaliot
t EOso ratio is defined as EOso in opioid-infused rats' EO'll in saline-infused fets"
.. Statistically significant shift
10
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OAOLE 10~gth
ED50=7.42(5.62-9.46)
21--~--~-_-~
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Figure 15A. NE dose-response curves (expressed as peak tall-flick latency In
seconds) detennined after the continuous I.t. Infusion of saline (1 ~1·h·1; .) or
CADLE (10 ~·h·f: .) for 6 days. NE Wf.lS tested on days 1-2 post-infusion and rats
received oolyane dose daily. Dalaare expressed as the mean ± SEM of 6-13 rats.
The corresponding EDso (95% CI) of i,l. NE, expressed in ~g, is indicated on the
figure.
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Figure 158. NE dose-response curves (expl"r,!'ssed as the maximum percent
effect) detennlned after the continuous i.t. infusion of saline (1 pl·h"; e) or
CADlE (10 lJQ'h'l; .) for 6 days. NE was lested on days 1~2 post·infusion and rals
received ontyone dose daily. Dala are expressed as the mean t SEM of6-13 rats.
The corresponding EDso (95% el) of i.t. NE, expressed in 1..19, is indicated on the
figure.
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3.2.5 Cross·To/erance Studies between DADLE and DX
The time course of tail-flick latency following the i.t. injectIon of OX (0.1 ~gl
to rats previously infused with saline (1 IJI'h-') or CADLE (10 j.J9·h·') for 6 days is
illustrated in Figure 16. Peakanlinociceptionwasobserved 15min after injection
and there was no significant difference between the two groups at any lime point.
Similar time-course experiments were conducted with 0.2, 0.3 and 0.5 ~ of OX
(data not shown). AUC analysis of the time-course data revealed no significant
difference between saline- and CADLE-infused rats for each Lt. dose of OX (Table
V). No sedation was observed with any of the doses of Lt. OX.
TABLE V. Summary of the Differences in the Area Under the Tail-Flick latency
versus Time Curve (AUC) Following the Intrathecal Injection of
Dexmedetomidine (OX) in Rats Previously Infused with DADLE or
Saline fO( 6 Days
OX DOSE (~g) TREATMENT (dose) AUC (s·min)
0.1 SALINE (1 ~I·h·') 268 ± 7
DADLE (10 ~g'h") 259 ± 16
0.2 SALINE (1 ~I'h") 255 ± 12
DADLE (10 ~g·h·') 265 ± 23
0.3 SALINE (1 ~I·h·') 290 ± 7
DADLE (10 ~g·h·') 326 ± 18
0.5 SALINE (1 ~I·h·') 370 ± 28
DADLE (10 ~g'h") 366 ± 34
No significance (P>O.05)
59
:§:5
ii'
c:
Ql
~
u. 4
I-
756015 30 45
Time (min)
o
31---.------.----,,---.,.--...::;:..---,
(15)
Figure 16. The time course of lall-flick latency following the acute I.t.lnjectlon
of OX (0.1 IJSII to rata previously infused with OADLE (10 J,lg'h"; .) or saline (1
~I·h·tj e). Data are expressed as the mean ± SEM of 4 saline- and 5 DADlE-
infused rats. There were no significant differences between the two groups
(unpaired Student's t-test or Mann-Whitney two-sample lest, where applicable).
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Peak tail-flick latencies (15 min) were used to construct the OX dose-
responsewves (Figure 17). The EDso and 95% CI for OX in DAOLE· and saline-
infused animals was 0.24 IJg (0.17-0.36) and 0.38 1J9 (0.29-0.49), respedlvely
(Table VI). For comparative pUfJX>S9S, dose-response curves were also conslructed
using the MPE (Figure 178). The corresponding EOso and 95%CI was 0.25 IJQ
(0.16-0.38) In DADLE-tolerant rats and 0.381J9 (0.2g..Q.50) in saline-controls (Table
VI). The slopes of the linear portion of ~he OX dose-respoose curves fO( both
treatment groups were parallel. Thus, there was no evidence of cross-tolerance
between OADLE and OX.
TABLE VI. EOso, 95% Confidence Interval (CI) and ED!ilI Ratio for Intralhecal
Dexmedetomidine Following Ihe Continuous Intrathecal Infusion of
Saline or DAOLE
TREATMENT (dose)
SALINE (1 ~I'h")
DAOlE (10 ~g'h")
SAliNE (1 ~I'h")
DADlE (10 ~g·h·')
EDso (95%CI)
ABSOLUTE LATENCY (s)
0.36 ~g (0.29·0.49)
0.24 ~g (0.17·0.36)
MAXIMUM PERCENT EFFECT
0.36 ~g (0.29.Q.50)
0.25 ~g (0.16·0.36)
EDso Ratiot
0.63
0.66
t EOso ratio Is defined as EOso In opioid-infused rals·EDso in saline-infused rals·1
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Figure i7A. OX doss-response curves (expressed as peak tail-flick latency in
seconds) detennlned after the continuous i.t. Infusion of saline (1 .,I·h·':.) or
DADLE (10 IJO·h";.) for 6 days. DX was tested on days 1·2 posl·infusioo and
separate groups of rats were used fO( each dose. Data are expressed as the mean
t SEM of 3-6 rats and the dashed lines rePfesent regression lines used to calculate
the E050 and 95°,{. CI (expressed in ~g as shown).
0.1 0.2 0.3 0.5
I.T. Cexmedetomldlne (IIg)
Figure 179. OX dose-response curves (expressed as the maximum percent
effect) determined after the continuous U. infusion of saline (1 ~I'h'l: .) or
DADL.E (10 IJg·h"j .) for 6 days, OX was tested on days 1-2 post·infusion and
separate groups of rals were used for each dose. Dala are expressed as the mean
:t SEM of 3-8 rats and the dashed lines represent regression lines used to calculate
the ED50 Blld 95% Cl (expressed in ~g as shown).
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3.3 Antagonist experiments
3.3.1 Differential Antagonism of Aforphine(201l9-h·'j· and DADLE (10IJg-h")-
Induced Ant/noe/caption by N./oxon.and Nsllr/ndole
To assess the relative selectivity of DADLE and morphine for IJ- and 6-opioid
receptors, respectively, during continuous i.1 infusion, nallrindole (1.0 mgokg-' )or
naloxone (1.0 mg'kg-1) was injected i,p. althe time of maximum antinociceplion (day
1 of infusion). Prior to naloxone, maximum tail-flick latency during morphine-infusion
was 9.0 5 (dashed line in Figure 18A; defined as 100%). After naloxone, the
morphine effect decreased to 48% and remained significantly antagonized from 15-
60 min (**P<O,01.,*P<O.05). The same dose of naloxone had a small but non-
significant effect on OADLE-induced anlinociceplion (P>O.05). The maximum tall·
flick latency dLling DADLE infusion before naloxone administration was 6.2 s (100%
effect). Neither naloxone nor naltrindole (1.0 mg·kg·1 i.p.) had any effect on
baseline tail-flick latency in rats continuously infused with Lt saline (data not shown).
The effect of the cS-selective antagonist. naltrinctoJe, on DADLE- and
morphine-induced antlnoclcepllon was determined in a separate experiment. The
maximum increase in tail·flick latency during DADLE infusion (6.4 s; 100% effect)
was significantly antagonized by i.p. naltrindole from 45-60 minutes (Figure 18B)
In contrast, naltrindole had no significant effect in rats receiving continuous 1.1.
morphine (peak tail-flick latency =8.7 s). Thesa data suggest that DADLE retained
its O·receptor selectivity in the eal1y period of continuous Lt. infusion; an observation
,..l..r.,.I.T
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Figure 18. The effect of naloxone (A; NX)or naltrindole (B; NTI) onlall-f1lck
latency during the continuous r.t infusion of morphine (20 ~g·h·1) and CADLE
(10llg·h-'). Naloxone and naUrindole (1.0 mg'kg" Lp.) were injected on day 1of
infusion. Data are expressed as the mean t SEM of 5 rats. Asterisks denole a
significant difference from peak anlinociception (before the antagonist) as
determined by repealed measures ANOVA followed by Newman-Keuls lest
(**P<O.01; *P<O.05).
6.
thai is consistent with the differential cross-tolerance results of this study.
3.3.2 Effect of Wyeth 27127 and Prazosln on Dexmedetomldln.-Induced
Antlnoclcepllon
To confirm the selectivity of high dose OX for a~·adrenoceptotS, and thus its
utility as a probe agonist in the cross-tolerance experiments, three separate groups
of naive rats were injoctedwith OX (0.5 ).19 U.) and the tail·fIick latency determined
15 min later. Ralswere then injected Lt. with either \NY 27127 (10 1J9; Q2-selective
antagonist), prazosin (10 I-Ig; a,-selective antagonist), or vehicle (DMSO; 5 1J1). The
anlinociceptive effect of OX was markedly antagonized from 30-60 min by \NY
27127 (Figure 19). In contrast, rals Ireatedwith prazosin showed no allenualion of
the antinociceptive effect of OX; the lime course was identical to receiving OX +
DMSO (Figure 19), OX ·"saline or OX alone. For the purposes of clarity, the latter
groups wafe omittej from the graph. AUC analysis of the lime course data for 'NY
27127-treated animals was also significanlly different from both the DMSO· and
prazosin·treated groups. These data confirm the Q 2-selectivity of i.1. DX at the
highest dose uSed in the cross-tolerance experiments (0.5 ~g).
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Figure 19. The effect of!.t. prazosln (PZ;.) • Wyeth 27127 (WY;I) or DMSO
(AI on dexmedetomldlne (DX)·lnduced antlnoclceptlon in three separate
groups of naive rata. Dexmedelomidine (0.5 1J9 Lt.) was injected at lime O.
Immediately aftertha is-min time point, prazosin (10 1-19), Wyeth 27127 (10 119) or
DMSO was injected i.t. toone of the groups. Data, expressed as themean fSEM
of 4-9 rats, were analyzed using one-way ANOVA followed by a Newman-Keuls test.
** Indicates a significant difference of Wyeth 27127-treated from both DMSO· and
prazosin·treated animals (P<O.01). '* Indicates a significant difference between
Wyeth 27127- and DMSO·treated rats (P<O.01); and between Wyeth 27127- and
prazosin-treated rats (P<O.05).
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".0 DISCUSSION
Endogenousopioid n noractenergicsystems are well recogllzed for !heir
abiity to independently modulate nociceptive transmission in !he dorsal hom alhe
spinal cord (see reviews by Cousins ard Mather. 1984;Yakshlrld Nouened, 1985;
Yaksh, 1985; Maze and Trarq.Jl1Ii. 1991). Nevertheless, phannacological evidence,
including the blockade of spinal a-acienergic antinociception by opicid antagonists
(Tung and Yaksh, 1982; Loomis at ai" 1987a; Yang el a/., 1994) and the
observation of cross-tolerance betweeo Lt. a-agonisls and opiold agooisls (Sherman
etal., 1988; Slevens el ai" 1966; Kalsoet sl.. 1993: Paul andTran, 1995), suggest
thai spinal noradrenergic modulation includes an endogenous opioid-depenc!ent
mechanism
The results of the pr9soo1 research provide further support for this
hypothesis, and in particular. the model illustrated n Figw8 1. Thus, the non-
selective a.agonist, NE. exhibited aoss-tolerance to DADLE, but not morphine. in
the rat as assessed by doS&{8sponse Malysis. In contrast, !he highly selective Q2-
agonist, Ox, exhibited no cross-tolerance to DADLE using lhe same experimental
paradigm. These data are also consistent with the results of acute experiments
investigating the anlinoclceptive interaction between spinal a," and a,w
adrenoceptors that preceded this work (Loomis et aI., 1992a; 1992b; 1993).
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".1 Re/,tlonshlp of the Present Work to Acute Studies of.n a,- .nd a;l-
Adfttroceptor Intellction
Alhresholddose ofMX (10 IJQ tt.), producing <5% MPE in the tail-flick lest
and 0% in the paw pressure lest, when combined with 1.1. OX significantly shifted the
OX dose response curve 10 the left, A combination of otherwise inactive doses of
MX+DX. effecting near maximal activity in the tail-flick test and Intermediate activity
in the paw pressure test, was significantly blocked by naloxone (30 \-19 i.l), lei
174,864 (751J91kg Lp.), or antiserum to Met-enkephalin (10 \-II i.t.)(Loomis at al.,
1992b). Moreover, pretreatment with the neutral endopeptidase Inhibitor SCH
32615 (75 "'Q Lt.), but not vehicle, further potentiated the MX+DX interaction
(additionallaftward shift. in the MX+DX dose response curve). The potency shift with
this combination exceeded lhe small effect of SCH 32615 on OX alone. These
results indicate that the acute synergistic Inferaction between i.t. OX and MX
involves a local enkephalin·dependent process mediated by spinal fi·receptors; a
mechanism supported by the well established interaction between exogenous
opioids and 02-agonists in lhe rat spinal cord. The blockade of this supra-additive
interaction by either prazosin (10 ~ I.L) or WY 27127 (0.5 ~g 1.1.) indicated thallhe
respective antinociceptive effects of MX and OX were mediated by distinct Q-
adt&noceptor sUbtypes.
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4.2 Conf/nuous Oplold Infusion and Tolerance
In the present study, dose-dependent anlinociceptlon was observecl with
continuous i.t. morphine (5, 10 and 20 lJg·h·1) in thslaH-f1ick test (mean peak lail flick
latency and AUC analysis of the time course dala). The time course dala are in
agreement with previous studies using osmotic mini-pumps for spinal drug delivery
(Milne eta'.. 1985; Russell et al., 1987; Slevensef al., 1988; Stevens and Yaksh,
1989a, 1989b, 1989c). Unlike the morphine experiments, only one infusion dose of
1.1. DADlE (10 lJQ'h·l ) was used. In preliminary experiments, a lower infusion dose
(31J9'h") yielding significant anlinociceplion was lested. However, thesa animals
rapidly recovered from tolerance (overnight) making cross-tolerance studies
impractical. Solubility limitations prevented a higher infusion dose of i.1. DADLE
from being used.
Continuous Lt. opioid infusion for 6 days induced significantlolerance to the
spinal aniinociceptive effect of morphine and DADLE. Tolerance was confirmed by:
a) the absence of antinociceplive activity of morphine or DADLE probe doses in
opioid~, but not saline-infused rats during the immediate post-infusion period; b) the
rightward (6-fold) shift in the morphine dose-response curve in morphine- es
compared 10 saline·infused rals; and c) the reversibility of this process upon removal
of the opioid (see below). These data indicate thai the decline in tail·flick lalency
during opioid infusion was the result of progressive pharmacodynamic changes 10
"
the continuous exposure of opioid receptors 10 their respective agonists (e.g.
uncoupling of 1.1- or O-feceptors from the effector mechanisms normally mediating
their enlinociceptive effects). II was not due to pump or catheter failure, repeated
behavioral testing, degradation of the opioid (Stevens and Yaksh, 1989b) or
pharmacokinetic factors (Yaksh, 1991).
The integrity of the drug delivery system was also confirmed by the dose-
dependent reduClion in body weight in opioid-, but not saline-treated animals during
the immediate post-infusion period. This effect, characteristic of opioid withdrawal
(Wei eI8f.• 1973; Suzuki et al., 1988; Cridland at ai" 1991) and reflecting a
decrease in food andlor water consumption durillQ the first 24 h, Is consistent with
the conllilUOUS delivery of opioid agonists via the mini-osmotic pump/catheter
system. Opiold-infused rats did not exnibil any signs of withdrawal when probe
doses of oploid· or a-agonists were tested, indicating that this abstinence effect had
a rapid onset and short duratioo.
4,3 Recovery from Oploid Tolerance
Significant recovery of anlinociceplive activity did not occur until 4 days after
the discontinuation of i.t. morphine infusion (5 J,Jg'h"). This time course provided a
3-day window in which to conduct cross-tolerance experiments without the
complication of concurrent rect:Yolery in opioid sensitivity. In the interests of time and
efficiency, recovery was determined using only the lowest infusion dose of
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rrorphine. Since the magnitude of spinal opioid tolerance is dependent on the I.t.
infusion dose (Stevens and Yaksh, 1989c), the lime course of recovery from 10 and
20 1J9'h-1 morphine should not be less than 3 days. Accordingly, cross-tolerance
eKJl6riments were limited to 3 post·infusion days in morphillEl-toleranl rats.
In vivo studies of the rale of offset of opioid tolerance have yielded variable
results, depending 0f'I the opioid agonist, the route of drug administration and the
behavioral measure of opiold activity. Using a stereotypical pattern of automatic
Mning activny ("ruming fir) in mice, Goldstein and Sheehan (1969) estimated the
lime of .-eeovery from levorphanol tolerance (induced with 20 mg'kg" Lp. every 8 h)
10 be equal to rate of onset of tolerance (approximately 48 h). Although not
quantitatively measured, these investigators noted that. in some experiments,
CW1algesic tolerance appeared to develop considerably more slowly than tolerance
10 the running fit. Cox et a/. (1975) measured the anlinociceptive response in rats
(paw pressure withdrawal test) to a standard infusion of morphine (5 mg·kg·h·' tv.)
+cycloheximide (200 mg·kgtJ·' i. v.) to prevent the further developmenl of tolerance
at various time intervals efter cessation of repeated s.c. morphine injectioos. A
biphasic pallern of recovery, consisling of an initial rapid phase (4 days duration)
and second prolonged phase (mean half-time of 13 days) was reported; a
comparable recovery pattern was also ObSElfVed in mice. Tung et al. (1981) induced
analgesic tolerance (hot-plate test) using once daily inj£'-clions of Lt. morphill9 (45
~g) for 8 days. Seven days after the termination of chronic morphine, rats regained
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85% of their initial responsiveness to l.t. morphine. Yaksh (1991) reported a 50%
recovery of the Lt. morphine ED50 in the rat hot-plate lest, nine days after terminating
a continuous l.t. morphine infusion (20 nmoUh). In contrast, ~-receplor binding and
anlinociceplive activity of PL 017 were restored 3 days after the continuous l.t.
infusion of PL 017 was discontinued in the ral (Nishino et al., 1990). Although time
course dala provide no specific information about the molecular/cellular events
underlying tolerance, the prolonged af,j sometimes biphasic recovery after chronic
morphine treatment implies that multiple factors are involved.
Recent studies using continuous Ll. infusion of receptor selective agonists in
rals indicate thai opioid tolerance in vivo is based on pharmacodynamic rather than
pharmacokinelic factors nor is it the result of learned behaviour (e.g. associative
tolerance). Thus, tolerance is observed only after the activation of spinal opioid
receptors, the degree of opioid tolerance is proportional to both the log of the
infusion dose and the fradional receptor occupancy of the agonist used, and there
is minimal loss of response between agonists which interact with distinct receptors
(e.g. minimal cross-tolerance between jJ, 6, % agonists) (Stevens and Yaksh,
19B5a,b; 1992). These data are consistent with t:1E. down-regulation of a fraction of
the spinal opioid receptOf population ancYor an uncoupling of opioid receptors from
their corresponding effector system.
Evidence from studies using NG 108·15 and 7315c ceUs in culture
(expressi:t (; and jJ receptors, respectively) indicate that the induction of tolerance
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in these cells involves two phases (see review by Johnson and Fleming, 1989).
Acute changes, characterized by rapid onset and rapid recovery (e.g. min 10 hours)
and initiated by high concentrations of agonist, include receptor desensitization (e.g.
the functional uncoupling of ~ and (5 receptors from their associated G proteins (Law
st al., 1983; Pu!tfarcken et al., 1988]) followed by internalization of uncoupled celt
surface receptors into Iysosomes where they are degraded (Law st al., 1984).
Receptor desensitization occurs prior to any change in the number of opioid binding
sites. Long·lerm changes, characterized by slow onset and slow recovery (e.g.
days to weeks), may reflect altered expression or repression of mRNA for specific
proteins (e.g. receptors. G-proleins, ion channels, ion pumps, enzymes of 2nd
messenger systems). For example, chronic morphine administration to the rat has
been shown to dxfease mRNA coding for PQMC in the hypothalamus (Mocchelli
etal., 1989).
The relevance of these observations to the progressive loss of opioid activity
in conscious behaving animals remains to be determined. As noted above, many
characteristics of opioid tolerance in vivo can be explained by the functional
uncoupling of opioid receptors from the G proteins linking them to their effector
systems (Cox, 1991). Concurrent changes in cholecystokinin activity, an important
phy~iological modulator of morphine analgesia, has also been implicated in the
development of opioid tolerance (Xu at al., 1992; Zhou at al., 1992; Hoffmann and
Wiesenfeld-Hallin, 1994). Interestingly, tolerance to opioids acting on spinal O·
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receptors is not altered by pharmacological manipulation of cholecystokinin neurons.
Our dala are consistent with the lime-dependent recovery of functionally coupled
~- and 6-oploid receptors and/or from compensatory changes to cholecystokinin
neurons in the case of ~-receptors.
Unlike morphine, significant recovery from OADLE tolerance was apparent
3 days after discontinuation of DADLE infusion (1 0 ~g'h") and complete by day 4.
On the basis of these data, cross-tolerance studies with NE or OX were carried out
on days 1-2 post-infusion in all DADLE-Iolerant rats. Our results are similar to lhose
of Russell at al. (1987) who reported a slightly slower rate of recovery to the I-i-
agonist. PL017 (0.5 ~g·h·l Lt.) as compared to DAIJLE (2 ~g·h·ll.l.) in the ral.
Complete recovery from PL017 and CADLE tolerance was observed on days 6 and
5, respectively. The modest difference in recovery between DADLE and morphine
is probably related to the lower intrinsic activity of morphine (Stevens and Yaksh,
1989c) and/or differences in the selectivity of the two agonists for their respective
opioid receptor subtypes (see review by Yaksh and Noueihed, 1985; Russell at al.,
1987).
4.4 Cross~To/erance Between Spinal Oploids and a-Adrenergic Agonlsts
In an early stUdy using continuous i.t. infusion of morphine (10 ~g·h·j for 5
days) followed by NE (15 IJg'h"' for 7 days), Milne and co-workers (1985) reported
significant cross-tolerance in the rat tait-flick test. The absence of antinociceplive
activity in morphine tolerant rats was not due to the oxidation of NE in the osmotic
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mini-pump (as confirmed by the f1uOfomelric analysis of NE taken from the pumps
at the end of the experiment). However, only one dose of 1.1. morphine and NE was
tested. Since the extent of tolerance, and the development of cross-tolerance, is
influenced by the dose of the tolerance-inducing agent (Slevens at al., 1986), we
used three different infusion doses of morphine, and three probe doses of NE (for
quantitative dose-response analysis) in the present experiment.
Animals made tolerant to i.1. morphine using three infusion doses (5, 10 and
20 IJg·h·1) exhibited no significant cross·tolerance 10 i.1. NE in the tail-flick test. While
there was an apparent atlemlation of low dose NE in rats trealed with 10 IJQ·h"
morphine. no such effect was observed in rals infused with a higher dose of
morphine (20 ~'hO') indicating that this trend was nol pharmacologically significant.
Previous studies reporting cross-tolerance between continuous i.t. morphine (0.76-
7.6I-1g·h01 ) and test doses of ST-91 (Stevens at al., 1988), and between morphine
(10 IJg'h-') and i.t. oxymetazoline (29.7 1-19) (Sherman at al., 1988) in the rat
hypothesized that re-distribution of morphine 10 the brain during i.t. infusion, and the
consequent activation of descending noradrenergic fibers, was most likely
responsible for the observed interaction.
The locus of action of drugs injected into the spinal subarachnoid space is
an important consideration. Hydrophilic drugs like morphine undergo slow cephalad
migration in the CSF while more lipid soluble drugs can be redistributed via the
systemic circulation aflor uptake in the micf'Ovasculalure of the spinal cord. The cell
7S
bOdies of noradrenergic neurons modulating nociceptive transmission in the spinal
cord are located in pontine nuclei (Le. medial and lateral parabrachiar nuclei,
nucleus subcoeruleus, AS and A7 nucleus) (Proudfit, 1988; Jones, 1991), and
morphine, focally injected near lhese brainstem sites, evokes the release of NE from
nerve terminals located in the spinal dorsal horn (see review by Yaksh, 1985).
Thus, the rostral migration of mOlphine, and ils attendant activation of bulbo·spinal
noradrenergic fibers, can confound the interpretation of cross-tolerance studies in
the spinal cord.
The absence of cross-tolerance between morphine and NE in the present
study (using three different infusion doses), indicates that: 1) the locus of action of
morphine, delivered by continuous i.t. infusion, and thus the site of morphine
tolerance, was primarily in the spinal cord; 2) any rostral migration that did occur
was insufficient to effect detectable a-adrenoceptor tolerance; and 3) spinal ~­
receptors are unlikely to mediate the endogenous opioid component of spinal
noradrenergic anlinociception in the rat. A predominant spinal site of action is
consistent with the results of a previous study investigating the activation of
brainstem IJ-receptors during continuous Ll. mOl'phine infusion, Rats receiving twice
daily injections of s.c. morphine or a continuous infusion of morphine (1 lJQ'h") in the
brainstem subarachnoid space for four days exhibited pronounced rhythmic fictive
swallowing (300 per minute) 30 min after i.v, naloxone (Bieger at ai" 1992),
reflecting an alteration in the brainstem opioid receptors that modulate
7'
buc:c:opha'yngeal and esophageal activity, dYonically exposed to morphine. This
was six times greater than the response evoked by naloxone in rats trealed with
continuous i.t. morphine (5 ~'h" for four days). These dala indicate the limited
effect of spinal rT'IOl"phine on relevanl brainstem opioid receptors during continuous
i.l infusion, and are in agreement with a previous study (Loomis at al., 1987b)
demonstrating that: 1) the antinociceptive effect of i.p. morphine is unaffected by
tolerance to spinal morphine (10 lJ9·h·1 for 7 days); and 2) the distribution of an Lt.-
infused dye is almost entirely restricted 10 the spinal segments adjacenllo the lip of
the L.. catheter. Nevertheless, any differences in the roslral migration of morphine
between the present study and previous investigations using the same type of
delivery system are not easily explained.
a-Agonists. including NE, are known to induce aaJIe tolerance
(tachyphylaxis). Depending upon the intrinsic activity and the frequency 01
administration of the probe drug, this phenomenon can influence the interpretation
of cross-toJerance experiments. To minimize this potential problem, rats were
allowed to recover for 24 h between probe doses of NE, and an escalating dose of
NE was administered on subsequent post..jnfusion days (i.e. 2.51J9 NE on day 1, 5.0
I-Ig NE on day 2, etc). This lesting regimen was based on preliminary experiments
indicating that the antinociceplive effect of NE in saline-infused rats (5 and 10 I-Ig
i.l. on days 2 and 3 post-infusion, respectively), was identical to that observed in
naive rats, administered 3 days apart (data not shown). These results strongly
77
suggesllhal acute tolerance to NE was not a factor in this study.
Because of the rapid recovery from DADlE tolerance. cross~lolerance
experiments were limited to days 1 and 2 post-infusion. To assess the problem of
acute tolerance with daily i.l. injections of OX, probe doses were tested in saline-
infused rats on consecutive post-infusion days. The degree of acute tolerance
obseNed was sufficient to preclude the further use of this treatment schadule (dala
not shown). Instead, each rat received only one dose of OX during the 2-day
''window''.
If NE effects spinal anlinociception, in part, through the o,-adrenoceptor
mediated release of enkephalin (loomis et al., 1993), then down-regulation of the
spinal opioid receptors responsible for the inhibitory effect of enkephalin should
attenuate this NE response. Indeed, the EDso of i.l. NE was significantly reduced
in rats made tolerant to the i)-agonist, DADLE as compared to saline-infused
animals. It was not possible to test this hypothesis using selective Cll-agonists like
methoxamine or phenylephrine in this experimental paradigm because of the
exaggerated motor responses evoked by these drugs in the spinal cord. Such
effects confound the intepretalion of changes in behavioral responses to noxious
stimulation (e.g. TF test) as previously described (Section 1.5.2). To our knowledge,
this is the first study of cross·tolerance between DADLE and NE. Although the shift
in the EDso of NE was relatively small (2.54) in DADLE·tolerant rats, this was
expected given the spectrum of NE activity at both a-receptor subtypes (Loomis et
7.
a/., 1993), the predominant role of a2~adrenoceptors in spinal edrenergic
antinociception, and evidence for the dissociation of Q2-adrenoceptors from
endogenous opioid systems (Fleetwood-Walker at al.• 1965; Maze and TranquilH,
1992).
Further support for the research hypothesis is indicated by the absence of
cross-tolerance between DADlE and the highly selective o2-agonist, OX. These
results are similar to those of Kalso and co-workers (1993), who reported no crOS$-
tolerance between spinal Tyr-D-Ser(olbu)-Gly-Phe-leu-Thr (DSTBULET; 6-a900i51)
and i.1. OX in the rat as determined from electrophysiological recordings of dorsal
horn nociceptive neurons. In these studies. rats were administered two daily
injections oli.t. OX (5 ~g) for 10 days or LI./:STBUTLET (50 I-Ig> for 5 days before
receiving the probe doses of OSTBUTLET or OX, respectively. These behavioral
data provide further support for the dissociation of opioid- and %·mediated
mechanisms of spinal antinociceplion, as reflected in our model (Figure 1). The
attenuation of i.t. NE, but not OX, in rats treated identically with continuous i.t.
DADLE cannot be explained by the redistribution of DADLE to noradrenergic cell
bodies located in the brainslem. In such a case, both drugs would be expected to
exhibit cross-tolerance 10 OADLE. Thus, there is no evidence in either of the cross-
tolerance studies (morphine·NE or DADLE-NE/DX) to conclude thai sites of action,
other than those in the spinal cord, contributed significantly to observed results. In
view of the absence of the cross-tolerance between 1.1. morphine and NE, and
7.
between DADLE and OX (as assessed using dose-response analysis), similar
studies of 1.1. morphine and DX were not undertaken.
High doses of i.t. OX (1-61-19), (acule or continuously infused) are known to
induce profollld sedation in rats (Fisher at al., 1990; Kalso at al., 1991; Takano and
Yaksh, 1992; Takano and Yaksh, 1993; unpublished results). This is a supra-spinal
inhibitory effect thai arises from drug redistribution into the systemic circulation
(Savoia etal., 1986; Kalsoetal., 1991). It is important to nole that no sedalion was
observed at any of the doses used in the present experiments (0.1-0.5 1-19 i.t.).
Moreover, it is known thallhe anlinociceplive effect (TF lest) of Lt. ox in rats perists
beyond the time course of sedalion (Kelso et al., 1991).
All interesting observation was the apparent potentiation oi Lt. OX in DADLE-
tolerant animals. There was an parallel, but statistically nOfHignificant, leftward shift
of the OX dose-response curve in CADLE- as compared to saline-infused animals.
Such an observation has, to our knowledge, not been previously reported. This
effect was unlikely to be due 10 the inadvertent delivery of residual CADLE solution
during the i.t. injection of probe doses of OX (resulting in potentialion), since all
catheters were thoroughly flushed with saline following the removal of the osmotic
pump. Stress-induced antinociception, possibly related 10 the discontinuation of
OADLE infusion, also seems unlikely as we observed no abnormal behaviour attha
time of lesting nor were the baseline tail-flick latencies any different compared to
saline-infused rats.
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One possible explanation is that the sudden withdrawal of CADLE infusion
caused a "rebound" release of endogenous enkephalin. An increase in the
extracellular concentration of enkephalin might be sufficient 10 potentiale the
antinociceptive effect of OX, subsequently injected inlo the spinal subarachnoid
space. We did not determine enkephalin concentration in the present study but
there are reports of such changes in the brain (Simantov and Snyder, 1976) and
spinal cord (Cridland at a/., 1991) of morphine-dependent rats, and the
cerebrospinal fluid of humans (O'Brien at aI" 1988). Using nearly identical
conditions to those of the present study (continuous i.t. morphine infusion _5 ~g'h"
for 6 days), Cridland at al. (1991) reported a significant increase in met-enkephalin
immunoreactivity in the rallumbar and sacral spinal cord, 24 h after Lt. naloxone·
precipitated withdrawal. These changes were localized to the spinal cord; the
caudate-putamen and globus pallidus were unaffected by the naloxone challenge.
Moreover, the Lt infusion of morphine by itself (no naloxone) did not affect met·
enkephalin immunOfeaclivity in the brain or spinal cord. The delayed appearance
of this neurochemical change is in agreement with the lime course of OX
administration in the present study (Le. for the first day of OX testing). To the extent
that this mechanism is responsible for the increased activity of OX in OAOLE·infused
rats, our data suggest enkephalin levels may remain elevated for up to 48 h after the
infusion ;s discontinued. a should be noted that a similar synergisilic interaction
between OX and morphine would also be expected during opioid withdrawal, but this
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was not investigated in the present study. The interaction between endogenous
enkephali'l crd i.t OX is in agreement with the proposed model of spinal adrenergic
antinocic:eption (Figtxe 1). In fUIxe experiments. it would be useful to determine the
change in met-enkephalin irTVTU'lOreactivity as well as mRNA fO( met-enkephalin in
the spinal cord of naloxone·treated rats following the continuous i.l infusion of
DAOLE.
4.6 RfK'4Ptor Se/ecllvlty of Morphine, DADLE and D(f)(medetomidlne
The reliability of the cross-tolerance dala depend on a number of important
factors. These include; 1) the selectivity of morphine and DADLE for their respective
opioid receptor Subtype3 during continuous i.t infusion; and 2) the selectjvi~y of OX
as an agonist al 02-adrenoceplors.
The modest but seledive blockade of morphine by naloxone, and DADlE by
natbindole. on day 1 ofcontiruous i.I. infusion is the only direct evidence of IJ- and
a-receptor selectivity in the present study. CADLE has been reported to have
modest activity at IJ-feceptors (Tseng, 1983; Russell et al., 1987; Stevens and
Yaksh, 1992). Indeed, a low dose of i.p. naloxone yielded a small bUI non~
significant reduction In tail·fIick latency during DADLE infusion. However, systomic
naloxone is only J.10 times more potent against lJ·agonlsts such as morphine and
sufentanU, than against DADLE (Tung and Yaksh, 1982; see review by Yaksh and
Noueihed, 1985; Yaksh et a/., 1986). Significant and quantilati'iely greater blockade
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of DADLE was achieved with the O-selective antagonist, naltrindole. This Is In
agreement with previous in vitro results indicating the relative inhibitory potency of
naltrindole to be over 100 limes greater for DADLE than to( morphine {Portoghsse
et al., 1988}. It is also consistent with the failure of nallrlndole 10 affect morphine
antinociception in the present study, although a>nf1iding results with naltrindole have
been reported in vivo (Tiseo and Yaksh, 1993). \'!/hila the naloxone and nallrindole
data are only relevant 10 dAy 1 of infusion, they do correspond to the lime of
maximum antinociceplion with morphine and DAOlE. As discussed in section 4.4,
the selectivity of these agonists in our experimental paradigm is also inferred from
the outcome of the cross-tolerance experiments, and the different time-courses of
recovery from opioid tolerance. Although (O_Pen2, D-Pen5)enkephalin (OPDPE) is
more selective than DADlE at the 6-receptor (Clark et aI.• 1986), the large amounts
required for continuous i.l infusion and the related cost of OPOPE made it
impractical for use in this study.
To verify the Q2-seledivily of Ox, we tested the effect of both prazosin and
WY 27127 on OX (0.5 ~), reasoning that any activity at Q,-adrenoceptors would be
most evident with the highest probe dose. Prazosin (10 IJQ i.t.) was without effect
whereas the selective 0z-anlagonisl, WY 27127 (10 ~Q 1.1.), completely reversed Ox-
induced antinociception. It should be noted that the 10-IJQ dose of prazosin is well
above the i.t. dose (2.5 IJQ) thai blocked the tail-flick effect of the a,-selective
agonist, ST-567 (loomis and Arunachalam, 1992) and equal to the IO~ of i.t.
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prazosin (9.8~) in blocki1g i,t NE in the tail flidl test (lXlplbIished results). These
results indicate that the probe doses of OX used in the.present study had no
delectable activity at spinal 0l-adrenoceptors, consistent with the pronounced
selectivity of OX for o,·adrenoceptors (o2-selectivity ralio of 1620 versus 220 for
cIonidine; Virtanen et aJ. 1988), and the results of 0lI' cross-tolerance experiments.
Prazosin is a classical o,·selective anlagonist which has been used
extensively to characterize adrenergic binding siles and functional a-adrenoceplors.
In recent years, multiple subtypes of at· and Q 2-adrenoceptors have been identified
through the molecular cloning of eDNA/genes encoding for these receptors
(Lomasney at al., 1991). Binding experiments using cells that selectively express
specifIC a-adrenergic subtypes have shc:7M11hat prazosin, in addition to being an a,·
antagonist, binds to specifIC subtypes of a~enoceptors (Bylund, 1988; Lomasney
at al.. 1991). Moreover, studies on the spinal pharmacology of 02-agonists,
induding the rank order of antagonist potency, suggest that at least two subt'JP8s
or the aradrenoceplor (designated 02A anda~ effect antinociception in the rat
spinal cord. The 0 2A-feceptor, which is nol blocked by prazosin, mediates the
antinociceptive activity of agonists like OX and c1onidine. The o~-receptor, which
is blocked by high doses of prazosin, mediates the effect of ST·91 (Takano and
Yaksh, 1992; Takano et al., 1992). The failure of prazosin to block OX In the
present study is consistent with the high doses of i.t. prazosin required to block
o~receptors(IOil(l= 38 IJg; 95%CI = 22-65; ST·91 in rat hot-plate test), and the
8.
>100 IJ9 required to block OX or donidine at alA receptors (Takano and Yaksh,
1992). These dose-response data strongly suggest thai prazosin induced selective
o,-aclrenoceptor blockade in the present study.
The antagonist profile of WY 27127 at different sUbtypes of -:I;e 0l-feceplor
has not been reported but. on the basis of other published data (Takano and Yaksh,
1992; Takano at 8/" 1992. Millan, 1992), we believe thallhe effect of OX was
mediated by 02A·receptorS. Future experiments will be required to clarify lhis issue.
•US Antinociceptive Interaction Between Spfnal at· and uJoAdrenocepfofS
Clearly, the results of the present study provide no detailed mechanistic
information about the coupling of a,-adrenoceplors to the enkephalin-depondent
process in spinal a-adrenergic antinociception. Based on the available information,
we have proposed that the activation of o,-adrenoceptors results in an inctease in
the exttacellular cooc:enlra!ion of enkephalin which then effects anlinociceplion via
spinal6-opioid receptors located on relevant neurons of lhe nociceptive pathway.
In the absence of release studies, it is not known if the activaton of 0,·
adrenoceptors actually evokes release or merely facililales the slimulus-evoked
release of enkephalin. Future studies measuring the spinal release of this poptide
will be required to answer this and related questions. Moreover, it is unclear if this
is a direct excitatory effect on enkephalin neurons or whether this involves
intemuncial neurons. The role of other inhibitory inputs (e.g. GABA) in spinal 0,"
8S
induced modulation also remains to be investigated. This possibility, and the
tI'lderfying hypoth9sis that spinal a,-adrenoceptors participate in spinal adrenergic
anlinociception are supported by the recent report that NE modulates nociceptive
transmission in the substantia getalinosa of the ral by facililating GASA and glycine
inhibitory post-synaptic potentials through o,-adranoreplors (Baba et al.• 1995).
A., interaction between monoamine receptor subtypes is not unique in tho
central nerv:xJs system; an analagous situation has been shown 10 occur between
dopamine receptor subtypes. Using animal models of Parkinson's Diseaso,
conc.urrenl activation of 0,- and D2-receptors in the striatum and substantia nigra
produces an enhancement of motor skills and alleviation of the Parkinsonian
symptoms (Robertson. 1992a, 1992b). A similar effect on Fes expression in the
striatum following administration of a combination of 0.- and D2-~elective agonists
has provided additional support to( an this interaction wit: lin the dopatiill"le system
(Paul etat., 1992).
4.7 Significance of the Results
The results of this thesis provide additional evidence for an antinociceplive
interadion between opioid and a-adrenergic systems in the spinal cord of the rat,
effected by the concurrent activation of°1" and Q 2..adrenoceptors (Figure 1). These
results are important in our basic understandin~of a-adrenergic pain modulation,
and its relationship 10 ~inal opiolds. They indicate thai in the ral, a 1-adrenoceptors
••
could pray an important role in spinal anlinociceplion by potentiating the inhibitory
effects mediated by o2-adrenoceptors. These dala provide a pharmacological
explanation for the often conflicting results of cross-tolerance studies between i.t.
opioid and a-adrenergic agonists (Post et al., 1988; Solomon and Gebhart, 1988;
Ossipov et aI" 1989), and the sensitivity of i.1. a-agonisls to opioid antagonists (see
reviews by Yaksh, 1985 and Maze and TranquiUi, 1991). Based on our model, an
opioid component in spinal a-adrenergic modulation would be evident when spinal
o,-adrenoceplors, located on or linked 10 enkephalin.-eonlaining neurons, were
intentionally or inadvertently activated by the test agonist. Thus, the 0,/°2 selectivity
ralio and the dose of the a-agonist would be critical factors in the outcome of such
studies. It Is noteworthy that previous studies of opioid and a-adrenergic
interactions have generally used a-agonists with modest selectivity for a 2-
adrenoceptors (e.g. ST·91 and clonidine; see Virtanen et af., 1988).
To the exlentthat a comparable interaction occurs in human spinal cord (a
question yet to be investigated), these results also have significant implications in
the rational selection of a..agonists as -:pinal analgesics, and thus thE! drug regimen
used in the clinical management of pain. The functional interaction between spinal
01- and a 2-adrenoceptors shown in this and previous studies suggest that a low
dose combination of a,- and a 2-agonists could optimize adrenergic spinal analgesia.
Currently, analgesic doses of spinal clonidine produce adverse cardiovascular
effects that often require pharmacological intervention. These arise from the
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inhibition of sympathetic outflow following the interaction of clonidine with a,-
adrenoceptors on preganglionic sympatheli,; neurons. However, central Q,-
adrenoceptors oppose the hypotensive and bradycardic actions of clonldine. Thus,
the concurrent use of an at-agonist could potentially augment analgesia while
attenuating the adverse cardiovascular effects of Q,·agonists. Such a combination
may also represent a more rational approach to the treatment of chronic pain. The
overall reduction in a-receptor stimulation achieved by using a low dose
combination of Q1- and Q,-selective agonists may delay the development of
3nalgesic tolerance.
In summary, the results of this study are consistent with a spinal enkephalin-
dependent. i5-receptor mediated process in a-adrenergic antinociception. This
opioid componenl appears 10 be selectively coupled 10 oj·adrenoceplors, that may
facilitate the stimulus~voked release of enkephalin in the dorsal horn of the spinal
cord.
ss
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